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ABSTRACT 
A series of combilexin-like monoamidines has been synthesized by linking an intercala-
tive unit with the DNA minor groove binder DB 818 via “Click chemistry.”  DB 818 is a 
dicationic minor groove binder that has shown strong binding affinity to AT sequences.  The aim 
was to synthesize novel classes of DNA minor groove binders that are combilexin-like – minor 
groove binder / intercalator hybrid – as potential unique DNA binding agents and therapeutics 
against African Sleeping Sickness.  Additionally, a series of novel benzo[d]1,3,2-diazaboroles 
DAPI derivatives were also synthesized and investigated.  These boron compounds have the po-
tential to be strong DNA minor groove binders because of their lower pKa and act as potential 
chromophores for Boron Neutron Capture Therapy. 
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1     INTRODUCTION  
Over one million people are at risk from suffering African Sleeping Sickness caused by 
the parasite trypanosoma brucei.  Current drug treatments have harsh side effects and are en-
countering resistance from the parasite making the need for new therapeutics imperative.  The 
kinetoplast, a DNA containing organelle unique to the kinetplastidia class of parasites, has been 
identified as a therapeutic target against African Sleeping Sickness.  By exploiting the differ-
ences between host DNA and kinetoplast DNA, we aim to synthesize new classes of therapeu-
tics.      
Kinetoplast DNA (kDNA) is composed of multiple phased AT sequences that are some-
times interrupted by GC base pairs.  To investigate the development of new therapeutics, the 
kinetoplast DNA motif of multiple phased AT sequences was targeted by making modifications 
to two DNA minor groove binders with strong affinity for AT base pairs, DB818 and DAPI.  To 
address the fact that the kDNA sometimes has GC base pairs interrupting the AT sequences, in-
vestigations were done to link the strong AT minor groove binder DB818 with the GC affinity of 
intercalative units.  The hypothesis is that minor groove binder DB818 will act as an anchor for 
the intercalative unit.  Moreover, we hypothesized that compounds that are more sequence spe-
cific for kDNA should lead to less side effects for the patient.  Modifications were then made to 
the DNA minor groove binder DAPI by synthesizing benzo[d]1,3,2-diazaborole derivatives.  The 
hypothesis is that the lower pKa of a benzo[d]1,3,2-diazaborole derivative should make for 
stronger hydrogen bond interactions and thus strong DNA minor groove binding affinity.  An 
additional benefit of using benzo[d]1,3,2-diazaborole compounds is that they offer the potential 
for use as therapeutics for boron neutron capture therapy.  If successful, this will lead to novel 
2 
classes of compounds that treat African Sleeping Sickness at the DNA level and could possibly 
lead to a new way of combating tropical diseases.  
1.1 DNA 
Nature uses 2’-deoxyribonucleic acid (DNA) as the stable informational storage system 
for life.  The double helical anti-parallel structure of eukaryotic DNA was originally elucidated 
by James Watson and Francis Crick in 19531.  DNA consists of three major chemical motifs 
termed the nucleotide: the nucleobase (Figure 1, blue), the deoxyribose sugar (Figure 1, red), and 
the phosphate backbone (Figure 1, black).  The only variation among the four DNA nucleotides 
is found on the nucleobase – purines adenosine (A) and guanosine (G) and pyrimidines thymi-
dine (T) and cytosine (C). The nucleobases pair via hydrogen bonding in purine-pyrimidine base 
pairings of either AT or GC.  Although hydrogen bonding is usually a weak noncovalent bonding 
force, the summation of hydrogen bonding interactions along the length of DNA anti-parallel 
strands provides a strong and stable force keeping the strands together1.  DNA also occurs as 
single stranded units for biological information storage and regulation, but that topic is outside of 
the realm of this dissertation and will not be further discussed. 
 
Figure 1  Common chemical motifs in a nucleotide: nucleobase (blue), 2’-deoxyribose sugar (red), and phos-
phate backbone (black). 
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1.2 Structure 
Watson and Crick elucidated the structure for what has come to be known as B-form 
DNA.  Of the various forms of DNA – A-form, B-form, Z-form and etc. – B-form DNA is most 
prevalent in eukaryotic systems1.  DNA helical forms are defined by their properties of twist, 
turn, and helical direction.  The properties of different conformations of DNA are presented in 
the table below (Table 1).  Since B-form DNA is the major form relevant to the parasite 
Trypanosoma brucei (T. b.), it will be the only one discussed further in this dissertation. 
Table 1 DNA helix properties1 
 
 Helical sense describes how the double strands twist around one another and is either 
right handed or left handed.  It can be visualized by taking a rubber band, holding one end sta-
tionary, and twisting the other end either to the left or to the right.  Twist describes how adjacent 
base pairs rotate about the z-axis.  A twist of 0o means the base pairs are stacked upon one anoth-
er like blocks, while a 90o twist means they are stacked like a cross.  Base tilt describes how a 
base pairs seesaws (inclination, η) compared to the plane of an adjacent base pair.  Residues per 
turn describes how many base pairs there are in one complete turn of the helix which can be 
measured by the position of the phosphate backbone.  Rise is the vertical distance between adja-
cent DNA base pairs1.  Sugar puckering will be described later. 
Major Minor Major Minor
A-DNA Right 32.7 20 11 2.56 C3'-endo 2.7 11 13.5 2.8
B-DNA Right 36 -6 10 3.3 - 3.4 C2'-endo 11.7 5.7 8.8 7.5
C-DNA Right 38.5 -8 9.33 3.31 C3'-exo 10.5 4.8 7.5 7.5
D-DNA Right 45 -16 8 3.03 C3'-exo 8.9 1.3 5.8 5.8
T-DNA Right 45 -6 8 3.4 C2'-endo Wide Narrow Shallow Deep
Z-DNA Left -9, -51 -7 12 3.7
C3'-endo 
(syn)
8.8 2 3.7 3.7
Groove width (A) Groove depth (A)
Base tilt
τ
Residues 
per turn
Rise per 
bp
(A)
Sugar 
pucker
Conformation
Helix 
sense
Twist per 
bp
Ω (
O
)
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1.2.1 Phosphate backbone 
 The phosphate backbone links nucleotides to each other on a strand of DNA by 
forming phosphate diester bonds between the 3’ and 5’ positions on the deoxyribose ring.  Addi-
tionally, the phosphate backbone provides a sheath of negative charges along the side of the 
DNA strand.  The negatively charged phosphate backbone allows DNA strands to interact with 
water molecules and metal cations in its environmental matrix.  Anionic charged DNA also pre-
vents effusion of native DNA outside of nuclear or mitochondrial membranes1.  
The phosphate diester bond is stable chemically.  This is due mostly to the negatively 
charged oxygen which blocks nucleophilic attack on the phosphorus because of electron repul-
sion.  Phosphorus has a tetrahedral geometry with four oxygens attached: two forming the 
phosphodiester bonds, one double bonded phosphone bond, and the remaining oxygen singly 
bonded and negatively charged.  The negatively charged oxygen which persists is stable because 
the phosphodiester has a pKa ~ 1.5, well below biologically relevant pH1. 
1.2.2 Sugar pucker 
The D-ribose ring in nucleic acids is cyclized into a 5 membered furanose ring; for DNA, 
the –OH group at 2’ position is reduced to a hydrogen hence the name deoxyribose (for 2’-
deoxyribose).  To prevent steric interactions with the furanose substituents, the ring twists out of 
plane.  This twisting is called puckering and describes the placements of the 2’ and 3’ carbons in 
relation to 1’-C, 4’-C, and 4’O.  Puckering above the plane of the furanose ring (the plane is de-
fined by the 1’-C, 4’-C, 4’-O atoms) toward the nucleobase is called –exo and below toward the 
3’-phosphate group is called –endo.  C2’-endo indicates that the 2’-C is puckered up towards the 
nucleobase while at the same time the 3’-C is puckered down (-exo), but the puckering up of the 
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3’-C is greater than that of 2’-C.  Sugar puckering has a wide range of effects on DNA shape, 
characteristics, and groove widths1. 
1.2.3 Base pairs 
DNA base pairs are between a purine and pyrimidine and only of the type adenosine-
thymine and guanosine-cytosine.  The nucleobases have two forms, keto and enol, but it is the 
keto form that is prevalent and leads to DNA hydrogen bonding.  This is the antithesis to the fact 
that the enol form is chemically more stable.  The keto form ensures hydrogen bonding for strand 
annealing.  The classical and most abundant form of hydrogen bonding between base pairs is 
called Watson-Crick base pairs (Figure 2).  Watson-Crick base pairs are responsible for what has 
been known as the genetic code, ensuring that AT and GC always form base pairs together, 
forming the stability of the genetic code.   Despite the stability of Watson-Crick base pairs, be-
cause DNA is a dynamic molecule, other base pairings are possible as shown in Figure 31. 
 
Panel A       Panel B 
   
         Adenosine – Thymidine          Guanosine – Cytosine 
Figure 2  DNA base Watson-Crick base pairs: adenosine-thymidine (panel A) and guanosine-cytosine (panel 
B)  
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AT Reverse Watson-Crick     GC Reverse Watson Crick 
      
AT Hoogsteen        GT Wobble 
      
AT Reverse Hoogsteen            GT Reverse Wobble 
 
AT Reverse Hoogsteen 
 
AT Reverse Wobble 
  
Figure 3  Non Watson-Crick base pairs: Reverse Watson-Crick, AU Hoogsteen, AU Reverse Hoogsteen, AC Reverse 
Hoogsteen, GU Wobble, GU Reverse Wobble, and AC Wobble1. 
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1.3 Hydrogen bonding 
Hydrogen bonding is one of four non covalent bonds: van der Waals, electrostatic, Lon-
don dispersion, and hydrogen bonding.  Because hydrogen only has one electron, when covalent-
ly bonded to a highly electronegative atom, the electron density will be higher for the more elec-
tronegative atom leaving the hydrogen with a comparatively more positive character (hydrogen 
bond donors).  When this type of hydrogen is in close proximity to another highly electronega-
tive atom that has a lone pair of electrons or is in its anionic form (hydrogen bond acceptors), the 
hydrogen bond donor will become attracted to the hydrogen bond acceptor atom to form the hy-
drogen bond2,3.   
Lately, there has been some confusion colloquially as to what is a hydrogen bond with 
some branches of chemistry proclaiming hydrogen bonding with –SH and aromatic hydrogens.  
Historically, hydrogen bonding has been considered to only occur with oxygen and nitrogen co-
valently bonded to hydrogen as donor and oxygen and nitrogen as acceptors because of the large 
differences in electronegativities between oxygen and hydrogen and nitrogen and hydrogen (ap-
proximately 1.2 and 0.8 on the Pauling or Allen scales respectively).  However, recent claims of 
hydrogen bonding in the Biochemistry and Computational Chemistry communities has prompted 
IUPAC (International Union of Pure and Applied Chemistry) to revisit and change its definition 
of hydrogen bonding from  
A form of association between an electronegative atom and a hydrogen atom at-
tached to a second, relatively electronegative atom. It is best considered as an 
electrostatic interaction, heightened by the small size of hydrogen, which permits 
proximity of the interacting dipoles or charges. Both electronegative atoms are 
usually (but not necessarily) from the first row of the Periodic Table, i.e. N, O or 
F. Hydrogen bonds may be inter-molecular or intramolecular. With a few excep-
tions, usually involving fluorine, the associated energies are less than 20 - 25 kJ 
mol −1 (5 - 6 kcal mol −1)2. 
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In 2011, a new definition was proposed and published for public discourse and feedback to 
IUPAC. 
 
The hydrogen bond is an attractive interaction between a hydrogen atom from a 
molecule or a molecular fragment X–H in which X is more electronegative than 
H, and an atom or a group of atoms in the same or a different molecule, in which 
there is evidence of bond formation.  A typical hydrogen bond may be depicted as 
X–H…Y–Z, where the three dots denote the bond.  X–H represents the hydrogen 
bond donor. The acceptor may be an atom or an anion Y, or a fragment or a mole-
cule Y–Z, where Y is bonded to Z. In some cases, X and Y are the same. In more 
specific cases, X and Y are the same and X–H and Y–H distances are the same as 
well leading to symmetric hydrogen bonds. In any event, the acceptor is an elec-
tron rich region such as, but not limited to, a lone pair of Y or π-bonded pair of 
Y–Z.  The evidence for hydrogen bond formation may be experimental or theoret-
ical, or ideally, a combination of both…2 
 
But as of 2014, the definition for hydrogen bonding has not changed and further disposition on 
the status of the definition – change or no change – is not available.  However, the official defini-
tion may change in a future edition of the Gold Book (the official IUPAC guidebook for nomen-
clature). 
The proposed new definition is broader and allows for more leeway in what may be con-
sidered a hydrogen bond or not.  The new definition was proposed in 2011 and as of yet has not 
been formally accepted by IUPAC.  The fact that there is contemplation on updating the defini-
tion should be noted.  However, for the remainder of this dissertation, the more traditional view 
of hydrogen bonding will be taken and focus on hydrogen bonding with nitrogen or oxygen as 
the electronegative atoms, as these atoms have the only relevance when discussing the DNA 
double helix and minor groove binding. 
Despite the debate on what is a hydrogen bond, two properties of the hydrogen bond re-
main static.  Hydrogen bonds are directional with optimal orientation to the hydrogen of the hy-
drogen bond donor (HBD) at 180o to the direction of the lone pair on the hydrogen bond acceptor 
(HBA)4.  The energy of hydrogen bonds is approximately 2–15 kcal mol-1 with the strength de-
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termined by the Lewis acidity of the HBD and the Lewis basicity of the HBA5,6.  Ergo, HBD- 
and HBA-ability can be correlated to pKa7.  The “acceptability” of HBA have been further inves-
tigated by correlating pKb (or pKBH+)6,8,9 or the pKBHX index10,11.  In these systems, the basicity 
of an electronegative atom is used to elucidate the hydrogen bond acceptability of a HBA. 
Although HB is optimal at linear direction, bifurcated and trifurcated hydrogen bonds are 
possible4,12,13.  In a bifurcated hydrogen bond, a HBD is sharing a hydrogen with two HBA with 
the shorter of the two hydrogen bonds called the major component while the longer hydrogen 
bond is called the minor4.  Trifurcated hydrogen bonds, where a HBD shares a hydrogen with 
three HBA are rare4,12. 
1.3.1 Scales for hydrogen bond donors and acceptors
 
 
Traditionally, chemists used the acidity of the HBD or the basicity of the HBA to corre-
late the strength of the hydrogen bond.  Gilli et al. have done computational work were they con-
clude the best way to study hydrogen bonds is as the minimum point along a proton transfer 
pathway14.  Under this methodology acid / base equilibrium equations can be interpolated to de-
scribe the nature of hydrogen bonds.  The -log of the acid dissociation constant, Ka, is defined as 
pKa (-log Ka = pKa).  pKa describes the pH when an acid, HA, will dissociate into its conjugate 
acid and base (eq. 1).  However, pKa is useful for HBD’s but pKa or pKb scales are less useful as 
predictors for HBA’s. 
Equation 1  Acid dissociation equation 
 
When hydrogen is bonded to another atom, due its one proton, the sharing of electrons 
tend not to be equal and less favorable towards sharing with hydrogen.  This facet of covalent 
hydrogen bonding is important when hydrogen is bonded to the highly electronegative atoms ni-
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trogen or oxygen.  Because of the large difference in electronegativities between oxygen and hy-
drogen and nitrogen and hydrogen (approximately 1.2 and 0.8 on the Pauling or Allen scales re-
spectively), most of the electron cloud density is located on the more electronegative atoms and 
not hydrogen.  This phenomenon increases hydrogen’s positive character making it more attrac-
tive to other anionic or electronegative species.  In the case of hydrogen bonding, hydrogen is 
attracted to highly electronegative atoms with a lone pair of electrons, forming a weak non cova-
lent bond.  Hydrogen bond acceptors are either oxygen or nitrogen with available lone pairs.  The 
free lone pairs are attractive to hydrogen covalently bonded to an oxygen or nitrogen.  Nitrogen’s 
HBA strength increases with the p character of its lone pair; therefore, delocalization of a lone 
pair as part of conjugation and/or a ring system decreases the HBA-ability of nitrogen6.  Albeit, 
analysis of crystal structures by Nobeli et al. show that nitrogen in heterocycles are better HBA 
than oxygen in heterocycles15.  These conclusions are supported by data in the pKBHX in-
dex16,17,18. 
By differentiating hydrogen bonding by the pKBHX index instead of pKa or PKb, one can 
make more precise predictions of hydrogen bonding interactions in lieu of acidity or basicity 
which may lead to other non-desirable acid-base side reactions.  The pKBHX index is fairly new 
but is beginning to be implemented in chemical synthesis.  For example, W. Wang et al. recently 
used the pKBHX index to optimize gold ligands for catalysis for which a strong base would be 
deleterious for the catalytic cycle16. 
1.4 Minor groove binders 
There are four ways for external molecules to interact with DNA: electrostatic interac-
tion, major groove binding, minor groove binding, and intercalation1.  Most small molecules syn-
thesized in laboratories target the minor groove due to the stabilization of the interaction by the 
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small width of the groove providing van der Waal’s interactions in addition to hydrogen bonding 
with protruding HBD’s and HBA’s of the nucleobases.  The HBD’s and HBA’s of the 
nucleobases can be read like brail providing a mechanism of specific sequence recognition.  
There are more HBD’s and HBA in the DNA major groove; however, synthesis of small mole-
cules that reversibly bind in the major groove has been difficult, in part, due to the loss of van 
der Waal’s contact in the wider major groove.  Nevertheless, proteins have evolved sequence 
specific structures for recognizing the HBD’s and HBA’s and fitting protein structures into the 
major groove (in addition to other protein-DNA stabilization factors)1. 
Minor groove binders usually consist of aromatic rings covalently linked by sigma bonds.  
The archetypes for minor groove binders are the natural products netropsin and distamycin (Fig-
ure 4).  In netropsin and distamycin, the HBD’s and HBA’s are found along in the non-aromatic 
portions of the molecules in the forms of amidine, amide, and guanidine functional groups.  First 
isolated from the Streptomyces genus of bacteria – netropsin from S. netropisis and distamycin 
from S. distallicus – netropsin and distamycin provide the framework for identification of other 
natural product minor groove binders as well as synthesis of unnatural ones.  Ligands synthetic 
and natural based on the framework of netropsin and distamycin are termed lexitropsins1. 
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Figure 4  Netropsin and distamycin 
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1.5 DAPI 
 
Figure 5  DAPI (4’6-diamidino-2-phenylindole) 
DAPI (4’6-diamidino-2-phenylindole), shown in Figure 5, was first synthesized in 1971 
by Dann et al.19,20, in an effort to explore diamidines as anti-trypanosomal agents.  DAPI was not 
effective as an anti-trypanosomal drug, but found continued use as a fluorescent probe for DNA 
and RNA21,22.  The fluorescence of DAPI increases upon binding to DNA or RNA22,23,24,25,26.  
DAPI stains both nuclear and mitochondrial DNA27.  DAPI has been shown to have two different 
binding modes: minor groove binding for dsDNA AT sequences and intercalation for dsDNA 
GC and dsRNA sequences23,28,29.  It has been shown that minor groove binding to AT sequences 
is more favorable due to the narrow groove width of AT base pairs, increasing van der Waal con-
tact of the molecule with the floor of the groove.  The AT minor groove binding is further stabi-
lized by a bifurcated hydrogen bond by the indole to thymine30. 
1.5.1 Benzimidazole-DAPI 
 
Figure 6  Benzimidazole DAPI (BzDAPI) derivative 
Benzimidazole DAPI (BzDAPI, Figure 6) derivatives have been explored as possible an-
ti-fungal agents31,32 and as enzyme inhibitors33,34.    Richard Tidwell et al. explored the use of 
BzDAPI derivatives as antifungal agents against the fungi Candida albicans and Cryptococcus 
neoformans31 because data in a previous study conducted in their laboratory showed a correlation 
between antifungal activity and dicationic molecules35.  The results showed very low activity of 
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BzDAPI with MIC (minimum inhibition concentration) of 100 and 50 µg/mL against C. albicans 
and C. neoformans respectively.  A QSAR and in vitro study of BzDAPI against C. albicans by 
Galvez et al. showed the same result: MIC = 100 µg/mL32.  Both studies showed low activity for 
BzDAPI but gave no explanation as to why.  Tidwell noted that compounds with good DNA 
binding ability also had good antifungal activity and that DNA binding ability may be essential 
to antifungal activity31, and work done by Wilson et al. showed that BzDAPI has good DNA 
binding ability36. 
Kubata et al. showed that there are two binding modes for BzDAPI just as in the parent 
DAPI compound37.  A CD spectrum of BzDAPI with CT DNA (calf thymus DNA) showed hy-
pochromic and redshifting with no clear isobestic point which the authors point out as meaning 
that there are at least two binding modes.  The flow dichroism spectrum of BzDAPI bound to CT 
DNA showed negative absorption in the DNA base pair region from 280 – 300 nm and nearly 
zero to positive absorption for the drug absorption region from 300 – 360nm with the authors 
explaining that the zero dichroism is indicative of two binding modes and the positive dichroism 
meaning that groove binding is the predominant binding mode.  By measuring the CD and fluo-
rescence energy transfer of BzDAPI with poly[d(AT)]2 and d(GC)2 DNA, Kubata et al. further 
showed that BzDAPI has two binding modes for AT sequences, groove binding and intercala-
tive, and one binding mode for GC sequences, intercalative. 
1.5.2 DB293 and DB818 
Work done by Tidwell et al. showed that bisbenzimidazoles have a high affinity towards 
AT sequences.  To explore small molecules that bind to DNA for AT sequences for the treatment 
of the parasitic diseases African Sleeping Sickness, Chagas Disease, and Leishmaniasis, Boykin 
et al. synthesized many small molecule diamidines, of which this dissertation will only mention 
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two: DB293 (Figure 7) and DB818 (Figure 8).  DB75 (Furamidine, Figure 7) has better activity 
against African Sleeping Sickness than one of the current treatments, Pentamidine (Figure 7), 
and with less side effects38.  A prodrug of DB75, Pafuramidine (Figure 7), had made it to Phase 
III Clinical Trials.  Because investigations have shown that benzimidazoles can increase DNA 
binding affinity38,39,40,41, a benzimidazole analog of DB75 was made: DB293.  
    
        
Figure 7  Top left - DB75 (Furamidine), top right – Pafuramidine, bottom left - DB293, bottom right - 
Pentamidine 
 
The substitution of a phenyl ring in DB75 for a benzimidazole (yielding DB293) did in-
crease the DNA binding affinity but only slightly.  Tm experiments by Wilson et al. to an AATT 
oligomer showed a ∆Tm of 11.3 and 14.0 oC for DB75 and DB293 respectively at 1:1 ligand to 
DNA ratio and 12.0 and 14.1 oC for DB75 and DB293 respectively at 2:142.  What is unique 
about DB293 is its ability to recognize GC base pairs and preferential binding to ATGA se-
quence via a cooperative 2:1 ligand to DNA binding ratio42,43,44,45.  In addition to DB293’s pref-
erential binding to ATGA, it also has a binding motifs to other AT sequences at 4 base pairs 
long42,43,44,46,47. 
 
Figure 8  DB818 
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To improve the binding of DB293, several analogs were investigated one of which was 
the change of the furan ring in DB293 to thiophene: DB818 (Figure 8).  DB818 binds 10 times 
more strongly to AATT (in a Drew-Dickerson dodecamer) compared to DB29338,39.  The large 
positive induced CD spectrum above 300 nm obtained by Wilson et al. is indicative of DNA mi-
nor groove binding38.  DNA footprinting, SPR, and Tm experiments performed in the same lab 
also support the claim that DB818 binds 10 times more strongly to AATT than DB293.  A crys-
tal structure of DB818 bound 1:1 to the Drew-Dickerson dodecamer leads to explanation of the 
higher binding38.  By changing from oxygen to a sulfur, the change in torsional angles allows the 
–NH of the benzimidazole to form a bifurcated hydrogen bond with the exocyclic thymine keto-
oxygens.  The amidines are also positioned for favorable hydrogen bonding contacts38.  The 
aforementioned contacts cannot occur with DB293 because the smaller oxygen atom in the furan 
ring makes the overall structure more concave in comparison to DB818.  This concavity will not 
allow both favorable positioning of the benzimidazole for hydrogen bonding and favorable hy-
drogen bonding of the terminal amidines with the minor groove.  In summary, the change from 
furan to thiophene in the analogues DB293 and DB818 can be termed as making DB818 more 
isohelical to the curve of the DNA groove. 
1.6 Intercalators 
Intercalators are planar, aromatic molecules that insert themselves parallel between the 
stacking of two sequential base pairs.  The planar aromatic ring systems tend to be extended 
       
     Ethidium         Proflavin    Adriamycin 
Figure 9 Examples of intercalators 
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electron deficient ring systems (figure 9).  Intercalators were first described by Lerman in the 
1960s48,49.  Upon intercalative insertion, the DNA phosphodiester backbone relaxes and the DNA 
strand lengthens.  This causes a decrease to 26o base pair per turn from 36o resulting in unwind-
ing and bending around the intercalative site,48,49,50.  DNA intercalation is stabilized by π-π stack-
ing interactions, van der Waals interactions, and hydrophobic interactions48,50.  Intercalators have 
an affinity for GC base pairs because of the lower energy requirements to unwind DNA at this 
site1.  However, there are some intercalators that intercalate at AT sites51, so the full mechanism 
of intercalation needs more study. 
The neighbor exclusion principle states that intercalators can only bind at maximum eve-
ry other base pair site; therefore, intercalation at 2 adjacent sites is prohibited48,49,50.  This is a 
result of the decrease in torsional angles in the phosphodiester backbone at the intercalative site, 
making intercalation at an adjacent site unfavorable.  Researchers, however, have been able to 
work with the neighbor exclusion principle and have synthesized bis- and tris- intercalators.  
These are intercalators linked together and can therefore intercalate at 2 or 3 nonadjacent sites. 
1.7 Combilexins 
 Combilexins are hybrids of minor groove binders and intercalators.  Combilexins 
were first introduce in the 1980s by Krivtsora52 and Dervan53.  Most intercalators have some as-
sociation with a minor groove binding ligand (and are combilexins by the strict definition of the 
word), but the term intercalator is still used regardless of the combilexin like properties such as 
nogalamycin (Figure 10)54.  Therefore, combilexins may be better thought of as the purposeful 
synthetic hybridization of a lexitropsins and an intercalator; although, it should be noted that 
there are some combilexins that are naturally occurring such as echinomycin (Figure 11)54.   
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Figure 10  Nogalamycin (left) and echinomycin (right)54 
 
The guiding principle behind the design of combilexins was to design a potential thera-
peutic or DNA probe that combined the general AT specificity of a minor groove binder with the 
GC specificity of an intercalator54,55.  An example of a synthetic combilexin was synthesized by 
Bailey et al. combining netropsin minor groove binder with an aminocridine intercalator (Figure 
11)55.  As of date, there are no combilexin therapeutics on the market. 
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Figure 11  Combilexin molecule hybridizing netropsin (fragment highlighted in red) with aminocridine (fragment high-
lighted in blue)55. 
1.8 Kinetoplastidia 
 Kinetoplastidia is a class of parasites distinguished by occurrence of a unique disc shaped 
organelle called the kinetoplast.  There are two orders in this class: Bodonida and 
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Trypanosomatidae.  Trypanosomatidae is of importance to human epidemiology particularly the 
protozoa trypanosma brucei, trypanosoma cruzi, and Leishmaniasis56,57.  
1.8.1 Protozoa 
 Kinetoplastidia are unicellular protozoans distinguished by the organelle kinetoplast.  The 
kinetoplast is inside the mitochondria and at the base of the flagellum.  The disc shaped 
kinetoplast is perpendicular to the axis of the flagellum58 and contains DNA (kDNA) for mito-
chondrial protein functions.  kDNA is a set of DNA different from mitochondrial DNA 
(mtDNA) and nuclear DNA and represents about 30% of the total amount of DNA in the proto-
zoa58.  The protozoa have a large, sometimes elongated flagellar pocket, crystalline lattice like 
paraxial rod, an undulating outer membrane, and a conspicuous glycocalyx.  Kinetoplastidia also 
have an organelle for glycolytic reactions called a glycosome, a special type of peroxisome58, 
and splice short RNA segments onto every molecule of mRNA within the protozoa.  Of im-
portance to the work of this dissertation, the glycosome is also the site of de novo pyrimidine 
synthesis and purine salvage, among other metabolic functions. 
1.8.2 Kinetoplast DNA 
 Kinetoplast DNA (kDNA) is a network of catenated circles composed of minicircles and 
maxicircles58.  There are approximately 10,000 – 20,000 minicircles and 20 – 40 maxicircles per 
kinetoplast organelle.  kDNA minicircles range from 500 – 2,500 base pairs and maxicircles, 
20,000 – 40,000 base pairs58,59.  Maxicircles encode mitochondrial proteins for cellular respira-
tion and are regulated and edited by kDNA minicircle transcripts58,59,60 although maxicircles do 
contain some gene self-regulation products59.  The proteins produced by maxicircles are similar 
to proteins produced by the mitochondria of higher eukaryotes58,60.  Minicircles are usually 
linked to only three neighbors and that number changes to six upon replication59,60.  Replication 
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of kDNA is complex and there are still some unknown factors.  What is mainly agreed upon in 
the literature about kDNA replication is 1) replication occurs during the cellular S phase (unlike 
mtDNA), 2) the minicircles detach from the catenated network for replication and are not repli-
cated while a part of the network, 3) after replication the minicircles contain at least one knick 
until all minicircles have been replicated, then the knicks are covalently closed prior to cell divi-
sion, and 4) maxicircles do not detach from the catenated network for replication60.  Much less is 
known about maxicircle replication than minicircle replication.  kDNA is exchanged between 
Kinetoplastidia during mating59. 
1.8.3 Trypanosoma brucei 
 In human pathology, Trypanosoma brucei is further divided into two subspecies: 
Trypanosoma brucei gambiense (T. b. g.) and Trypanosoma brucei rhodesiense (T. b. r.).  The 
subspecies Trypanosoma brucei brucei only affects cattle causing the disease nagana.  
(Throughout this dissertation, the use of the terms Trypanosoma brucei or T.b. refers to both sub-
species T. b. r. and T. b. g.)  Morphologically, these three species of Trypanosoma appear the 
same but are considered three distinct species for historical reasons56,57. 
Trypanosoma brucei undergoes several morphological changes during its lifecycle which 
is delineated by the position of the kinetoplast56,57.  The metacyclic trypomastigotes is the infec-
tive form to humans.  It is transferred to the host via the saliva during a blood meal by an infect-
ed tsetse fly (glossina species).  Once in the host, the metacyclic trypomastigote transforms into a 
trypomastigote in the blood and spreads throughout the host.  After infection, trypomastigotes 
transform into the intermediate trypomastigote then stumpy trypomastigote which is the only in-
fective form to insect vector during a blood meal.  When a tsetse fly uptakes the stumpy 
trypomastigote, the hindgut becomes infected with the parasite and it multiplies there.  After ~10 
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days, it migrates to the forgut for ~10 days then onward towards salivary glands over an addi-
tional 10 – 15 days.  In the salivary glands, it undergoes metamorphosis into an epimastigote and 
multiplies.  After several generations of multiplication, the epimastigote transforms into infective 
metacyclic trypomastigotes, starting the infective cycle again56,57. 
1.8.3.1 Pathogenesis 
Not all species of Glossina (tsetse fly) are vectors for Trypanosoma brucei.  For T. b. g., 
the infective species are palpalis and tachinoides56,57.  For T. b. r., the infective species are 
morsitans, pallidipes, and swynnertoni56,57.  Upon infection of the host after a blood meal from 
an infected tsetse fly, and transformation from a metacylclic trypomastigotes to trypomastigotes 
in the blood stream, the parasites spread into intertissue fluids – mostly lymph nodes, spleen, and 
cerebrospinal fluid56,57.  The parasites do not invade cells.   
Trypanosomes are unable to synthesize their own purines and must salvage them from 
the host.  Purine salvaging and a high number of parasitemia lead to the symptoms of the infec-
tion.  Despite being morphologically similar, T. b. g. and T. b. r. progress differently and present 
different signs of infection.  T. b. g. infection is a more chronic illness while T. b. r. is more 
acute.  As T. b. g. progresses, there is usually a small sore at site of initial infection and rapid re-
production once in blood and lymphatic system.  T. b. g. infection progresses more slowly com-
pared to T. b. r.  The course of untreated T. b. g. infection rarely lasts longer than 6-7 years.  The 
symptoms are intermittent fevers, headaches, muscle and joint aches, malaise, itching of the skin, 
swollen lymph nodes, and weight loss.  T. b. r. infection progresses more rapidly presenting the 
same symptoms as T. b. g. but within 1-2 weeks.  Additionally, some people develop a rash at 
the site of initial infection and a large bump on the neck called a Winterbottom’s sign which is a 
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swollen lymph node.  Invasion of the central nervous system occurs after a few weeks and death 
ensues usually within months for T. b. r.56,57 
Sleeping Sickness is the end stage of trypanosome infection and caused by invasion of 
the parasite into the central nervous system.  Symptoms include confusion, reduced coordination, 
disruption of the sleep cycle, bouts of fatigue, mental disturbances such as irritability, lack of 
concentration and personality changes, motor system involvement, development of seizures, and  
paralysis.  Finally the patient becomes indifferent to their surroundings, more difficult to rouse, 
and comatose.  Additional symptoms can include encephalopathy, psychotic reactions, hypoxic 
brain damage with convulsions, and heart failure56,57. 
Trypanosoma brucei is able to evade the host’s immune system by changing glycoprotein 
coat every two weeks56,57.  This process is call antigenic variation.  Variable-specific surface gly-
coprotein (VSG) is coded for by ~1000 genes and makes up about 20% of the parasites genome.  
The Variant Antigenic Types (VAT) are expressed by the VSG gene at the end of the chromo-
some and the VSG is change to another VSG gene behind it to express a new VAT56,57.  Conse-
quently, patients experience bouts of fever when a new VAT is expressed followed by a tempo-
rary remission when the host’s immune system gains a foothold over the antigens followed by 
another bout of fever when the new VSG express the next VAT.  This mechanism is why at-
tempts at vaccination have proven unsuccessful and is the reason why identification of an effec-
tive therapeutic option is imperative56,57. 
1.8.3.2 Epidemiology 
According to World Health Organization, the number of new cases of African Sleeping 
Sickness in 2012 was 7197.  In 2006, that number was approximately 11,50061.  In 2008, Fevre 
et al. published that the number of people at risk of catching the disease was over 1.3 million62.  
22 
Over 95% of the cases of T. b. g. human infection are found in Democratic Republic of Congo, 
Angola, Sudan, Central African Republic, Chad, and northern Uganda.  Ninety-five percent of T. 
b. r. human infections are found in Tanzania, Uganda, Malawi, and Zambia61. 
Currently, there is no vaccine or prophylaxis leading to preventive measures being the 
only way to minimize infection rates.  The most widely implemented preventative measures used 
are minimizing contact with tsetse flies, trimming and removal of brush where tsetse flies are 
found, use of the insecticides DDT and benzene hexachloride, inspecting vehicles before enter-
ing, and wearing long-sleeved shirts and pants.  Permethrin-impregnated clothing and insect re-
pellent have not been proven effective against tsetse flies56,57,61. 
1.8.3.3 Diagnosis 
The diagnosis rests on finding the parasite in body fluid or tissue by microscopy.  The par-
asite load in T. b. rhodesiense infection is substantially higher than the level in T. b. gambiense 
infection.  T. b. rhodesiense parasites can easily be found in blood.  They can also be found in 
lymph node fluid or in fluid or biopsy of a chancre.  The classic method for diagnosing T. b. 
gambiense infection is by microscopic examination of lymph node aspirate, usually from a poste-
rior cervical node. It is often difficult to detect T. b. gambiense in blood.  All patients diagnosed 
with African trypanosomiasis must have their cerebrospinal fluid examined to determine whether 
there is involvement of the central nervous system, since the choice of treatment drug(s) will de-
pend on the disease stage. The World Health Organization criteria for central nervous system 
involvement include increased protein in cerebrospinal fluid and a white cell count of more than 
5. Trypanosomes can often be observed in cerebrospinal fluid in persons with second stage infec-
tion56,57. 
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1.8.3.4 Current treatments 
Drugs for the treatment for T. b. g. and T. b. r. infection are Suramin, Pentamidine, 
Melarsoprol, Eflornithine, and Nifurtimox.  These drugs are available in the U.S. only from the 
CDC.  All of the current treatments for African Sleeping Sickness have severe side effects.  The 
side effects of Suramin are exfoliative dermatitis, pyrexia, nephrotoxicity, kidney damage, col-
lapse with nausea, vomiting, shock, severe diarrhea, and jaundice; Melarsoprol, encephalopathy, 
liver toxicity, severe enterocolitis, fatigue, arthralgia, myalgia and fever, pruritus, urticaria, tach-
ycardia, palpitations, chest pain, hypotension, and phlebitis; Pentamidine, hypotensive reactions, 
damage to liver, kidneys, and the pancreas; Eflornithine, encephalopathy, and gastrointestinal 
symptoms, bone marrow toxicity resulting in anaemia, leucopenia, thrombocytopenia, alopecia, 
fatigue, arthalgia, dizziness, insomnia, fever, headache, and anorexia; Nifurtimox, anorexia, pol-
yneuropathy, nausea, vomiting, headache, and vertigo56,57. 
1.9 Suzuki coupling 
Introduced in 1979 by N. Miyaura, K. Yamada and A. Suzuki, Suzuki coupling is a car-
bon-carbon coupling reaction that links organoborons and organohalides / pseudo-halides via a 
palladium(0) catalyst and a base (Eq. 2)63.  This method is formally known as the Miyaura-
Suzuki Coupling, but for the remainder of this dissertation, it will be referred to by its commonly 
known name: Suzuki Coupling.  For this work A. Suzuki won a Nobel Prize in 2010 (along with 
R. Heck and E. Negishi).  Suzuki coupling has become a popular coupling method because the 
reactants are readily commercially available and usually inexpensive, nontoxic, and air- and wa-
ter stable and a variety or reaction conditions are tolerated63.  Electron deficient organoborons 
work best for reaction kinetics, but the reactivity of the halogen used is more important which is 
as follows: I >>Br~OTf>> Cl64,65,66. 
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Equation 2  Suzuki coupling (Y = OH, OR, or halogen) 
 
The Suzuki coupling mechanism is illustrated in Scheme 1.  The first step Suzuki cou-
pling (and most carbon-carbon palladium catalyzed coupling reactions) is oxidative addition (Eq. 
3).  The palladium(0) complex coordinates with the carbon-halogen bond oxidizing to a palladi-
um(II) complex, inserting the palladium between the carbon and the halogen.  Oxidative addition 
is the rate determining step in the Suzuki reaction64,66.  The type of halide affects reaction kinet-
ics hence the aforementioned ranking (I >>Br~OTf>> Cl) and a variety of organohalides are able 
to participate in Suzki coupling given the proper conditions: alkyl-, alkenyl-, alkynyl-, allyl, ben-
zyl-, and arylhalides66.  However, alkylhalide with β-hydrogens are problematic because the oxi-
dative addition step is very slow64. 
 
Scheme 1  Suzuki coupling mechanism 
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Equation 3 Oxidative Addition Mechanism 
 
The next step in the catalytic cycle is transmetallation (Eq. 4).  While developing the 
Suzki Coupling method, workers in Suzuki’s lab was initially unsuccessful because – as they 
surmised – the organic group was not nucleophilic enough to migrate to the palladium intermedi-
ate63,64,67.  In order to activate the organoboron compounds for transmetallation, Suzuki’s group 
added base in order to make a quarternized borate complex the makes the organic group more 
nucleophilic for 1,2 migration to the palladium intermediate.  The nucleophilic organic group 
from the boron displaces a leaving group on the palladium complex forming a new palladium 
complex with the new organic group attached.  Workers in Suzuki’s lab found that for aryl-aryl 
coupling, weak bases work best for less hindered arylboronic acids – K3PO4, Na2CO3, and 
NaHCO3 – and strong bases work best for hindered arylboronic acids like NaOH and Ba(OH)264.  
Workers in Suzuki’s lab also found that strong bases like NaOH, TlOH, and NaOMe work well 
in THF/H2O systems and weak bases like K3PO4 and K2CO3 work well in dimethoxyethane 
(DME) systems66.  Clearly, the type of base added needs to be evaluated for each system indi-
vidually. 
Equation 4  Transmetallation Mechanism (X = leaving group) 
 
Because the carbon-carbon bond is stronger than the carbon-palladium bond, the adjacent 
carbons in the palladium(II) complex will form a bond while disassociating their carbon-
palladium bonds.   The new carbon-carbon bonds form the coupled product while the palladium 
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is reduced from a 2+ oxidation state to a 0 oxidation state.  The reduction of palladium from 2+ to 
0 also drives the reductive elimination step forward and regenerating the catalyst (Eq. 5). 
Equation 5  Reductive Elimination Mechanism 
 
1.10 1,2,3-Triazole 
1,2,3-Triazoles have historically been made by Huisgen cycloaddition.  Huisgen 
cycloaddition is a [3 + 2] cycloaddition between an azide and an alkyne yielding the 1,4- and 
1,5-regioisiomers in a 1:1 mixture (Eq. 6).  Huisgen cycloaddition must be done at high tempera-
tures and is not regiospecific.  The Huisgen reaction is a typical 1,3-dipolar cycloaddition where 
a dipole (an azide) adds to a dipolarophile (terminal alkyne) in a concerted [3 + 2] cycloaddition 
reaction.  The Huisgen reaction was actually discovered by Arthur Michael at the end of the 19th 
century, but Rolf Huisgen is the one who fully developed its chemistry and elucidated its mecha-
nism in the 1960s68.  The drawbacks to the Huisgen reaction are that it is very slow and high 
temperatures are required for good yields.     
Equation 6  Huisgen cycloaddition 
 
1.10.1 “Click chemistry” 
The idea of “Click chemistry” was first presented in 1999 by Sharpless, Kolb, and Finn at 
the 217th annual American Chemical Society meeting.  The idea came about by the group exam-
ining how nature synthesizes large biomolecules.  They noticed that nature synthesizes large bi-
omolecules in small simple steps and assembles them like blocks.  They suggested that synthetic 
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Chemists emulate the same thing to obtain pharmacologics quickly and reliably.  In 2001, 
Sharpless et al published a paper describing the approaches of “Click chemistry” and defining its 
meaning69.  “Click chemistry” should be 1) modular and wide in scope, 2) highly efficient and 
give high yields, 3) yield easily removable or no by-products, 4) be stereospecific, 5) consist of 
readily available starting materials and reagents, 6) the product should be benign or easily re-
moved, 7) purification should involve simple techniques, and 8) the product should be stable un-
der physiological conditions69. 
There are several reactions that meet most of the criteria outlined by Sharpless and are 
thus considered “Click chemistry” reactions: Diels-Alder cycloaddition, oxidative addition, Mi-
chael Addition, non-aldol carbonyl Chemistry (formation of urea, oxime, hydrazone), 
nucleophilic ring opening (of epoxides, aziridines, and aziridinium), and catalyzed 1,3-dipolar 
cycloaddition69,70.  Copper-catalyzed 1,3-dipolar cycloaddition is usually thought of as the defi-
nition of “Click chemistry” because it is the most popular reaction.  Its popularity is due to the 
reaction being one of the simplest and least troublesome to purify; however, Cu-catalyzed 1,3-
dipolar cycloaddition is not the single definition of “Click chemistry.”  “Click chemistry” en-
compasses many reactions that fit the profile delineated by Sharpless. 
In 2002, Meldal and Sharpless independently discovered a copper catalyzed Huisgen re-
action (Eq. 7)71.  The Cu-catalyzed Huisgen reaction is 107 times faster than the uncatalyzed one, 
can be done in a temperature range between 0 and 160 oC and a pH range of 5 -12, and is 
regiospecific for the 1,4-regioisomer71.  Furthermore, Sharpless showed that this reaction can be 
done in polar media (i.e. water, ethanol, t-BuOH, etc…)70.  The main downside to this reaction is 
that it can only be done with a terminal alkyne.  The accepted reaction mechanism is shown in 
Scheme 2.  In the first step, the terminal alkyne forms a π-complex with a copper of the catalytic 
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dimer.  The pKa of the terminal alkyne lowers by ~9.8 units to ~21 because of the π-complex.  
This allows deprotonation by the base leading to a copper-acetylide complex.  Next, the azide 
displaces a ligand from the copper dimer and binds to the other copper in the species.  The ter-
minal nitrogen of the azide, N3, attacks the alkyne carbon farther from the copper, C4.  This 
forms a metallocycle which leads to the attack on the C5 carbon by the N1 nitrogen in the azide.  
The base then deprotonates C5, regenerating the catalyst and freeing the 1,4-disubstituted 1,2,3-
triazole71. 
Equation 7  “Click chemistry” synthesis of 1,4-disubstituted 1,2,3-triazole via copper catalyzed Huisgen 
cycloaddition 
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Scheme 2  A) Mechanism for the copper catalyzed Huisgen reaction yielding 1,4-disubstituted 1,2,3-
triazole70,71 and B) Mechanism for ruthenium catalyzed Huisgen reaction yielding 1,5-disubstituted 1,2,3-
triazole72,73. 
 
A 
B 
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In 2005, Zhang in collaboration with Sharpless and others, discovered the regiospecific 
1,5-disubstitued Huisgen reaction using ruthenium as a catalyst74.  Unlike the copper catalyzed 
reaction, the ruthenium catalyzed reaction may use either terminal or internal alkynes.  The reac-
tion mechanism has not fully been elucidated since this reaction is fairly new; however, the pro-
posed mechanism is shown in Scheme 2.  The first step is oxidative coupling of the alkyne and 
azide with the ruthenium metal.  The terminal nitrogen of the azide, N(3), attacks the (previous-
ly) alkyne carbon farther away from the ruthenium metal to form a metallocycle.  The ruthenium 
catalyst is regenerated and the 1,5-disubstituted 1,2,3-triazole is freed by reductive elimination75. 
1.11 Benzimidazole 
o-Phenylenediamines are used to synthesize benzimidazoles through two methods: a con-
densation reaction with a carboxylic acid or oxidative cycloaddition with an aldehyde using an 
oxidizing agent76.  Condensation of o-phenylenediamine with a carboxylic acid usually requires 
harsh conditions like high temperatures and concentrated sulfuric acid or polyphosphoric acid 
(Eq. 8).  Oxidative cycloaddition requires less extreme conditions but toxic solvents, prolonged 
reaction times, and toxic metal by-products are problematic (Eq. 9)76,77.   Oxidizing agents in-
clude but are not limited to p-benzoquinone, nitrobenzene, tetracyanoethylene, benzofuroxan, 
DDQ (2,3-dichloro-5,6-dicyano-p-benzoquinone), IBD (diacetoxyiodobenzene), 
boronotrifluoride etherate, iodine and hypervalent iodine, ozone, CoCl2•6H2O, Co(OH)2, CoO, 
FeCl3•6H2O, FeBr3, HfCl4, MnO2, Pb(OAc)4, Cu(OTf)2, In(OTf)3, Sc(OTf)3, Yb(OTf)3, 
VO(acac)2-CeCl3, Zn-proline, ZrCl4, ZrOCl2•8H2O, gold/CeO2, TsOH/graphite, N,N-
dimethylanilin/graphite, cobalt(III)salen complex on activated carbon, , KHSO4, H2O2, 
(NH4)2S2O8, SO2, sulfamic acid, and atmospheric air76,77,78,79.   
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Equation 8  General synthesis of benzimidazoles from condensation of phenylenediamine and carboxylic acid 
 
Equation 9  General synthesis of benzimidazoles from oxidative cycloaddition of phenylenediamine and an 
aldehyde 
 
 
A number of variously substituted benzimidazoles are known to be good anti-parasitics in-
cluding DB293 and DB818.  The reasons why have not been elucidated, but for trypanosome, it 
is believed that benzimidazoles are recognized by a purine transport system and thus shuttled in-
to the protozoa.  Likewise, these benzimidazoles have also been shown to be good DNA minor 
groove binders, recognizing AT base pairs39. 
1.12 Amidine 
Amidines are carboxylic acid analogues with an amino group and an imino group (Figure 
12)80.   There are five types of amidine classifications: 1) unsubstituted, 2) monosubstituted, 3) 
symmetrical disubstituted, 4) unsymmetrical disubstituted, 5) and trisubstituted (see Figure 12 
for details)81.  This dissertation will discuss only unsubstituted amidines.  Amidines can be used 
as precursors for the synthesis heterocycles such as imidazolones, imidazoles, benzimidazoles, 
pyrimidines, and triazines81.  This lab has found success using amidines for their DNA AT base 
pair recognition and ability to allow transport into trypanosome and leishmania protozoa.   
 
Figure 12  Amidine structure: 1) unsubstituted, R1 = R2 = R3 = H; 2) monosubstituted, R2 = R3 = H; 3) sym-
metrical disubstituted, R3 = H; 4) unsymmetrical disubstituted, R1 = H; 5) and trisubstituted  
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1.12.1 Amidine Synthesis 
Amidines are usually synthesized by the Pinner reaction.  Named after its discoverer, 
Adolf Pinner, who synthesized unsubsituted amidines from nitriles by passing anhydrous hydro-
chloric acid through anhydrous alcohol, then dissolving the intermediate imidate ester in ammo-
nia dissolved in alcohol (Eq. 10)80,81.  Acyl cyanides should not be used with this method as it 
results in the ester and the poisonous gas hydrogen cyanide81.   
Equation 10  Amidine synthesis via Pinner reaction 
 
Since Pinner, other methods of amidine synthesis have been developed.  The Tafel and 
Enoch method involves treatment of an amide with silver nitrate and sodium hydroxide to make 
a silver-amide salt.  The silver-amide salt is then reacted with ethyl iodide in anhydrous ether 
followed by hydrochloric acid treatment to make the imidate ester hydrochloride salt.  Ammonia 
is used to convert the imidate ester to the amidine81.  The Bernthsen method converts thioamides 
into amidines with concentrated ammonium hydroxide and mercuric chloride to drive the reac-
tion to completion81.  Alkali metal amides in anhydrous solvents can be used to add to nitriles to 
produce alkali amidine salts that can be converted to amidines by hydrolysis in water or with al-
coholic hydrochloric acid at low temperatures81.  Nitriles can be converted into amidoximes us-
ing hydroxyl amine and the amidoxime converted into the amidine by catalytic hydrogenation81.  
Amides can be converted to the imidoyl chloride via chlorinating agents (such as thionyl chloride 
or PCl5) and the imidoyl chloride can be converted into the amidine with ammonia81.   
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1.13 Diazaboroles 
Boronic acids (Figure 13) have found a wide range of use in chemistry.  One use was al-
ready mentioned as a substrate for Suzuki coupling.  Boron is unique in that it is trivalent and is 
neutral with an empty p-orbital.  The empty p-orbital makes boron a Lewis acid – electron accep-
tor.  The pKa of phenyl boronic acid is Pka ~ 8.7 – 8.982 
 
Figure 13  Boronic Acid 
Benzo[d]1,3,2-diazaboroles, generally referred to as diazaboroles, are the result of con-
densation of a boronic acid, ester, halide, or BMe2R, with an o-phenylenediamine.  Condensation 
with alkyl amines or ethylenediamines are nonproductive.  There is not much literature on the 
chemistry of diazaboroles, but it is known that they hydrolyze under acid or base conditions.  
Synthesis of diazaboroles proceeds by a possible mechanism highlighted in the Scheme below.  
A nitrogen from a phenylenediamine attacks the empty pz orbital of a boron forming a borate in-
termediate that loses water and the new boron intermediate is attacked again by a nitrogen, form-
ing a borate complex, and losing water to form a diazaborole.  It is not known if these steps are 
associative or concerted83.   
 
Scheme 3  Possible synthesis mechanism for benzo[d]1,3,2-diazaborole 
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Diazaboroles are indole isosteres.  To the best of our ability, we have not found experi-
mental data on the pKa of diazaboroles, most likely due to its acid / base sensitivity.  However, 
the pKa of benzo[d]1,3,2-diazaboroles has been determined by molecular modeling (ACD Labs 
v.11.02) to be 3.9984.  This makes benzo[d]1,3,2-diazaborole more acidic than the corresponding 
2-phenylindole (pKa = 16.8)84 by ~ 13 pKa units and 2-phenylbenzimidazole (pKa  = 11.4)84 by 
~7 pKa units.  The lower pKa makes diazaborole a better hydrogen bond donor.  If successfully 
incorporated into a DNA binding motif, as a better HBD, it is hypothesized that using a 
diazaborole will result in stronger DNA binding and possible therapeutic use.  Moreover, the bo-
ron atom can be exploited for use in boron neutron capture therapy (BNCT) which will be dis-
cussed later. 
As mentioned earlier, diazaboroles are isosteres of indoles85.  The isoelectronic nature 
arises because boron has 3 valence electrons, nitrogen had 5, and carbon has 4.  So in the case of 
diazaboroles, the valence electrons of the two nitrogens bonded to boron equal 13 (5N + 5N + 
3B), and in the case of indoles, the number of valence electrons of the corresponding atoms is 
also 13 (5N + 4C +4C).  Diazaboroles are isoelectronic to indoles but the corresponding CN and 
CC bonds are approximately 0.1 Å longer because of boron’s larger radius86,87.  Boron is known 
to be able to participate in aromatic systems such as is the case in 1,3,5-borazine88.  The nitrogen 
lone pairs participate in π back donation to boron, adding electron density to the empty pz 
orbital89.  In diazaboroles, the same pi back bonding phenomenon seems likely.  Additionally, 
electron density is also donated to the boron pz orbital from the phenyl ring.  This leads to a con-
jugated aromatic, ring system.  X-ray crystallography of diazaboroles show a planar system90.  
Small dihedral angles 20.8 – 40.5o allow better p orbital overlap.  The average diazaborole B-N 
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bond length is ~1.41 – 1.44 Å86,91,92.  A single B-N bond is ~1.58 Å, and a double B=N is 
~1.4090,92,93.  However, it should be noted that some researchers have described such molecules 
as pseudo-aromatic (not to be confused with anti-aromatic). 
1.14 Boron neutron capture therapy 
Certain nuclei have the ability to be excited after neutron absorption.  High energy prod-
ucts are produced by the fission of the excited nuclei.  The utilization of this atomic process for 
medicinal purposes, first recognized in the 1930s by Locher, is termed neutron capture therapy94.  
Boron has been identified as an optimal atom for neutron capture therapy by Sweet95 because the 
10B isotope is 20% naturally occurring, the fission products are 4He2+ and 7Li3+, and the fission 
products are usually confined within the cell (5 – 9 µm)95 from which they arise lowering the 
chance of damaging neighboring tissues.  Historically, boron neutron capture therapy (BNCT) 
research has been focused on gliomas due to the sensitivity in treating malignant brain tumors 
rather than with traditional therapies – surgery, chemotherapy, and radiation.  The potential bene-
fits of BNCT can be less cellular damage to healthy cells if the boronated compound has higher 
uptake in malignant cells than nonmalignant cells96.  This is due to the fact that the fission prod-
ucts of BNCT are usually confined to the targeted cell, as aforementioned.  More recently, 
BNCT research interest has focused on for head, neck, and liver tumors. 
DNA targeting boron compounds have the potential for lower dosage in BNCT, minimiz-
ing side effects.  Moreover, most BNCT candidates that have made it into clinical trials are high 
molecular weight compounds with relatively high dosages (~100 – 900 mg / kg).  Synthesis of 
lower molecular weight compounds with higher efficacy would be invaluable to the field, partic-
ularly if they targeted DNA of malignant cells.   
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1.15 Microwave synthesis 
Microwaves are a part of the electromagnetic spectrum with frequencies from 0.3 to 300 
GHz.  All commercially available microwave ovens operate at 2.45 GHz as not to interfere with 
communication frequencies.  Microwave chemistry made its advent in the 1990s using conven-
tional microwaves bought from an appliance store.  Since then, the field has flourished and re-
search in this area is increasing97.   
The crux of microwave chemistry is acceleration of reaction rates by reaching high tem-
peratures via microwave heating.  Microwave heating occurs by the interaction of microwaves 
with dipoles and ions.  During microwave heating, dipoles/ions align with the applied electric 
field.  As the field oscillates, the dipoles/ions try to realign themselves with the alternating ap-
plied electric field.  The realignment process results in the loss of energy as heat.  The thermal 
energy comes from molecular friction and dielectric loss.  If the dipole does not have enough 
time to realign or if it realigns with the electric field to quickly, no heating occurs97.  This is an-
other reason why commercial microwaves operate at a frequency of 2.45 GHz; it is optimal to 
prevent nonheating by rapid or sluggish realignment.    
Microwave ovens produce microwaves using a magnetron.  A magnetron generates mi-
crowaves by interacting with a stream of electrons with a magnetic field inside a vacuum.  A 
waveguide then directs the resultant microwaves into the cavity (oven).  Domestic microwaves 
turn the magnetron on and off to produce variable power levels while heating.  This feature does 
not allow chemists much control when heating because the reaction mixture can cool and reheat 
during microwaving. 
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To offer chemists more control of their reactions, a line of industrial microwave ovens 
have been manufactured.  These microwaves dedicated for synthesis have several advantages 
over domestic microwave ovens.  The magnetron of industrial microwaves does not go through 
on/off cycles and thus are able to supply a continuous field.  They also have features that monitor 
reactions such as temperature monitoring by fiber optic probes and IR sensors and temperature 
and pressure regulation software.  Other control features are magnetic stirrers and fire safety con-
trols.  Industrial microwaves also come in monomode or multimode.  In monomode microwaves, 
the oven cavity is small to fit only one reaction vessel and is designed to produce a standing 
wave from the magnetron.  Multimode microwaves can fit several reaction vessels and a mode 
stirrer homogenizes the field from the magnetron in the oven98. 
A measurement of the ability of a substance to convert electromagnetic energy into heat 
is called the loss factor, tan δ.  The loss factor is defined by the equation tan δ = Є’’ / Є’, where 
Є’’ is the dielectric loss and Є’ is the dielectric constant.  Dielectric loss is the efficiency with 
which electromagnetic energy is converted into heat, and dielectric constant is the ability of the 
substance to be polarized by an electric field.  Therefore, heating characteristics are dependent on 
dielectric properties.  A high loss factor is defined to be > 0.5; medium, 0.5 – 0.1; and low, < 0.1.  
A low loss factor for the solvent does not mean that microwave heating cannot be done.  As long 
as one of the reagents in the reaction mixture has a higher loss factor, the microwave heating will 
be more efficient.  Moreover, if all components of a reaction mixture have lower than desired 
loss factors, the system can be “doped” with material with a higher loss factor that will in turn 
heat the system97. 
Traditional heating methods involve the transfer of thermal energy by conduc-
tion/convection.  Heating is transferred from the heat source to the system by thermal energy 
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transfer.  This process is dependent upon the thermal conductivity property of each medium 
transferring the energy.  On the other hand, microwave heating heats the reaction mixture direct-
ly.  Microwaves can travel through glass and directly interact with the reaction mixture, heating 
the bulk simultaneously98. 
Caveats to employing microwave heating are: industrial microwaves are expensive, risk 
of fires when working with a previously un-established microwave reaction, and microwave ef-
fects.  Microwave effects are the appearance of byproducts only seen with microwave heating.  
There are two types of microwave effects: specific and nonthermal.  Specific effects can be ra-
tionalized from rate acceleration or rapid/extreme temperature increases. Extreme temperatures 
can also occur not only from increased bulk temperature of microwave heating but also 
microspots that are drastically above the bulk temperature.  Specific effects have also been ra-
tionalized due to superheating (the heating of a substance, specifically the solvent in this case, 
above its boiling point without boiling); however, stirring prevents superheating and is not a 
problem using modern, dedicated industrial microwaves.  Nonthermal effects are the opposite; 
they are believed to be caused by the electric field lowering the pre-exponential factor (A in the 
Arrhenius equation K = Ae -∆G‡ / RT) due to the orientation effects of the dipolar molecules.  Acti-
vation energy may also be lowered because the entropy of activation, ∆S‡, is lowered due to mi-
crowave heating being more orderly than conventional heating97.  This leads to the advent of 
previously unseen byproducts. 
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2     EXPERIMENTAL 
2.1 General information 
Commercial reagents were used without further purification.  Melting points are uncor-
rected and were determined on a Mel-Temp 3.0 melting point apparatus.  All reactions except 
those involving amidine synthesis were monitored by TLC.  NMR spectra were recorded on a 
Bruker 400 MHz spectrometer.  11B NMR spectra were recorded with boric acid as an internal 
standard.  Mass spectra were obtained from Georgia State University Mass Spectrometry Lab.  
Elemental analysis was done by Atlantic Microlab Inc. in Norcross, GA.  Microwave reactions 
were carried out on a CEM Discover Legacy microwave reactor in 10 mL vials unless otherwise 
noted. 
2.2 Combilexin DB818 derivatives 
2.2.1 Suzuki coupling 
5-(4-Hydroxyphenyl)thiophene-2-carbaldehyde by Suzuki Coupling of 5-
bromothiophene-2-carbaldehyde and (4-hydroxyphenyl)boronic acid.  5-Bromo-2-
thiophenecarbaldehyde (26.4 mmol) and Pd(PPh3)4 or PdCl2(PPh3)2 (2.5 mol %) were dissolved 
in 80 mL of MeOH (methanol) / H2O (1:1) while stirring.  4-Hydroxyphenylboronic acid (26.4 
mmol) and 2N K2CO3  (39.5 mmol) were added in succession and the reaction mixture was heat-
ed at reflux for 3 days99 .  The reaction mixture was then cooled to room temperature, quenched 
with water, and vacuum filtered through celite with a small bed of silica.  The volatiles were 
evaporated using a rotary evaporator.  The remaining residue was extracted with ethyl acetate 
(100 mL) three times and the combined organic layers were washed three times with water (300 
mL) and once with brine (200 mL).  The organic layer was washed with 10% NaOH (200 mL) 
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three times and the combined aqueous layer was then neutralized with conc. HCl acid.  The re-
sulting precipitate was collected by vacuum filtration.  The product was heated at ~50 oC over-
night in a vacuum oven. 
Equation 11  Synthesis of I 
 
 5-(4-hydroxyphenyl)thiophene-2-carbaldehyde (I).  Yellow-orange 
solid, 58 % yield, mp = 202.4 – 203.6 oC; 1H NMR (400 MHz, DMSO-d6) δ = 10.02 (s, 1H), 
9.85 (s, 1H), 7.98 (d, J = 4 Hz, 1H), 7.64 (d, J = 8.4, 2H), 7.55, (d, J = 4 Hz, 1H), 6.86 (d, J = 8.4 
Hz, 2H); 13C NMR (100 MHz, DMSO) δ = 184.7, 159.3, 154.5, 140.9, 140.5, 128.5, 124.3, 
124.1, 116.8.  ESI-MS: m/z 205.10 (obsd), 205.03 (calcd) for (M+ +1). 
Following the procedure of Walton et al.100, 5-bromo-2-thiophenecarbaldehyde (6.0 
mmol) and 4-methoxyphenylboronic acid (7.2 mmol) were dissolved in 15 mL of PhMe (tolu-
ene) while heating to 80 oC while stirring.  Next, Pd(OAc)2 (0.36 mmol), PPh3 (1.2 mmol), and 
7.5 mL of EtOH (ethanol) were added in succession and the reaction mixture was heated at re-
flux overnight.  The reaction mixture was then cooled to room temperature, quenched with wa-
ter, and vacuum filtered through celite with a small bed of silica.  The filtrate was extracted with 
ethyl acetate (20 mL), washed with water (20 mL), then brine (20 mL), dried over Na2SO4, and 
reduced in vacuo.  The crude was purified by flash column chromatography packed with silica 
gel using DCM (dichloromethane) as eluent. 
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Equation 12  Synthesis of II 
 5-(4-methoxyphenyl)thiophene-2-carbaldehyde (II).  Orange-yellow 
solid, 74 % yield, mp = 118.0 – 118.7 oC; 1H NMR (400 MHz, DMSO-d6) δ =  9.87 (s, 1H), 8.00 
(d, J = 4.0 Hz, 1H), 7.75 (d, J = 8.9 Hz, 2H), 7.63 (d, J = 4.0 Hz, 1H), 7.04 (d, J = 8.9 Hz, 2H) 
3.81 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 183.8, 160.4, 153.0, 140.9, 139.5, 127.7, 
125.1, 124.0, 114.8, 55.4.  HRMS: 219.0479 (obsd), 219.0474 (calcd) for C12H10O2S (M + H)+. 
2.2.2 Alkylations 
General procedure for the alkylation of 5-(4-hydroxyphenyl)thiophene-2-
carbaldehyde.  Alkylation of I to produce alkyne III proceeded by adding propargyl bromide 
(6.75 mmol) to a stirring solution of I (2.25 mmol) and K2CO3 (2.50 mmol) in anhydrous DMF 
and heated at 80 oC overnight.  The reaction mixture was cooled to room temperature, quenched 
with water, vacuum filtered and heated at ~50 oC in a vacuum oven overnight.  (Author’s note: at 
larger scales, yield decreases, and crude product can be purified by flash column chromatog-
raphy packed with silica gel using DCM as eluent.) 
Equation 13  Equation 2  Alkylation of I with propargyl bromide  
 
 5-[4-(prop-2-yn-1-yloxy)phenyl]thiophene-2-carbaldehyde (III).  
yellow solid, 99 % yield, mp = 116.4 – 118.0 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.87 (s, 
1H), 8.00 - 8.04 (m, 1 H), 7.76 (d, J = 8.8 Hz, 2H), 7.63 - 7.69 (m, 1 H), 7.08 (d, J = 8.8 Hz, 2H), 
4.87 (s, 2H), 3.61 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = 183.8, 158.3, 152.7, 141.1, 
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139.4, 127.7, 125.7, 124.3, 115.7, 78.9, 78.6, 55.6.  ESI-MS: m/z 243.02 (obsd), 243.05 (calcd) 
for C14H10O2S (M + H)+. 
Alkylation of I to produce alkyne IV proceeded by passing N2 through a stirring solution 
of anhydrous DCM (20 mL) then adding trifluoromethanesulfonic anhydride (11.9 mmol) and 
chilling to 0 oC in an ice-water bath.   In a separate round bottom flask, N2 was passed through a 
stirring solution of anhydrous DCM (20 mL), but-3-yn-1-ol (26.4 mmol), and anhydrous pyri-
dine (1.0 mL) for 15 minutes and then chilled to 0 oC in an ice-water bath.  The but-3-yn-1-ol 
solution was transferred to the stirring trifluoromethanesulfonic solution dropwise via syringe 
while kept chilled at 0 oC under N2.  The reaction mixture was stirred for 1 hour at 0 oC then al-
lowed to warm to room temperature.  The solution was washed once with water (20 mL), dried 
over Na2SO4, and concentrated in a rotary evaporator to yield a rose colored liquid that was im-
mediately used without further purification.  Anhydrous DCM (10 mL) was added to the liquid 
and then chilled to 0 oC.  To the solution was added I (6.0 mmol) followed by Cs2CO3 (6.2 
mmol).  The mixture was stirred at 0 oC for 2 hours then stirred at room temperature for 2 days.  
The reaction mixture was then vacuum filtered, the filtrate concentrated in a rotary evaporator, 
and the product was obtained by flash column chromatography packed with silica gel using 
DCM as eluent.   
Equation 14  Alkylation of I with but-3-yn-1-yl trifluoromethanesulfonate (DCM = dichloromethane). 
 5-(4-(but-3-yn-1-yloxy)phenyl)thiophene-2-carbaldehyde (IV).  
Peach solid, 38 % yield, mp = 126.8 – 127.3 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.88 (s, 
1H), 8.01 (d, J = 3.9 Hz, 1H), 7.72 - 7.78 (m, 2H), 7.65 (d, J = 3.9 Hz, 1H), 7.03 - 7.09 (m, 2H), 
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4.13 (t, J = 6.5 Hz, 2H), 2.91 (t, J = 2.6 Hz, 1H), 2.67 (td, J = 6.5, 2.6 Hz, 2H); 13C NMR (100 
MHz, DMSO-d6) δ = 183.8, 159.3, 152.9, 141.0, 139.5, 127.8, 125.3, 124.1, 115.3, 81.3, 72.5, 
66.0, 18.8.  HRMS: 257.0643 (obsd), 257.0631 (calcd) for C15H12O2S (M + H)+. 
2.2.3 Azidations 
General procedure for the azidation of 4-chloroquinoline and bromoalkylnaphtha-
lenes.  4-Chloroquinoline (7.6 mmol) was dissolved in 15 mL of DMSO (dimethylsulfoxamide) 
and then NaN3 (19.38 mmol) was added.  The reaction mixture was heated to 100 oC and stirred 
for 5 hours.  After cooling to room temperature, the reaction mixture was poured onto ice, va-
cuum filtered, and the precipitate was recrystallized in petroleum ether101. 
Equation 15  Azidation of alkylnaphthalenes (X = CH, y = 1 or 2) and 4-chloroquinoline (X = N, y = 0). 
 
 4-azidoquinoline (V). Gray crystalline needles, 65 % yield; 1H NMR (400 MHz, 
CDCl3) δ = 8.80 - 8.88 (m, 1H), 8.07 (m, 2H), 7.75 (t, J = 7.5 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 
7.15 (d, J = 4.7 Hz, 1H).  13C NMR (100 MHz, DMSO-d6) δ = 150.3, 148.4, 145.0, 130.1, 128.7, 
126.4, 121.7, 120.7, 109.5. 
For 1-(2-azidoethyl)naphthalene, sodium azide (3.9 mmol) was added to a solution of 1-
(2-bromoethyl)naphthalene (2.2 mmol) stirring in 10 mL of DMF (dimethylformamide) and hea-
ted to 80 oC for overnight.  After cooling to room temperature, the reaction mixture was extrac-
ted with 10 mL of EtOAc three times and the combined organic layers were washed with water 
(30 mL) and brine (30 mL), dried over MgSO4, and concentrated in a rotary evaporator 102.  The 
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crude was purified by flash column chromatography packed with silica gel using ethyl acetate 
and hexane as eluent 
 1-(2-azidoethyl)naphthalene (VI). Brown liquid; 84 % yield; 1H NMR (400 
MHz, CDCl3) δ = 7.99 (d, J = 8.2 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 
7.56 – 7.47 (m, 2H), 7.44 – 7.37 (m, 2H), 3.63 (t, J = 7.4 Hz, 2H), 3.37 (t, J = 7.4 Hz, 2H).  13C 
NMR (100 MHz, DMSO-d6) δ = 134.2, 133.5, 131.4, 128.6, 127.2, 126.9, 126.1, 125.6, 125.5, 
123.4, 51.0, 31.5 
For 2-(azidomethyl)naphthalene, NaN3 (6.9 mmol) and 2-(bromomethyl)naphthalene (4.5 
mmol) were stirred in 20 mL of DMF at room temperature over the weekend.  The reaction was 
worked up as above following the method of Lee et al.102 
N3
 2-(azidomethyl)naphthalene (VII). White solid; 76 % yield; 1H NMR (400 MHz, 
CDCl3) δ = 7.87 – 7.83 (m, 3H), 7.77 (s, 1H), 7.51 – 7.49 (m, 2H), 7.42 (d, J = 8.4 Hz, 1H), 4.49 
(s, 2H).  13C NMR (100 MHz, DMSO-d6) δ = 133.0, 132.6, 132.4, 128.2, 127.5, 127.4, 126.8 
126.2, 126.1, 126.0, 53.7. 
1-(bromomethyl)naphthalene was stirred in MeCN with NaN3 (2.3 mmol) at 80 oC for 6 
hours103. The reaction was cooled to room temperature, concentrated in a rotary evaporator, and 
extracted with 20 mL EtOAc three times.  The combined organic layers were washed three times 
with water (50 mL), dried over MgSO4, concentrated in a rotary evaporator and heated at ~50 oC 
in a vacuum oven overnight overnight.  The azide was used without further purification.   
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Equation 16  Azidation of 1-(azidomethyl)naphthalene 
 
 1-(azidomethyl)naphthtalene (VIII). Brown liquid; 1H NMR (400 MHz, CDCl3) δ 
= 8.03 (d, J = 8.2 Hz, 1H), 7.91 – 7.86 (m, 2H), 7.60 – 7.16 (m, 3H), 7.47 – 7.43 (m, 1H), 4.76 
(s, 2H).  13C NMR (100 MHz, DMSO-d6) δ = 133.4, 131.2, 131.0, 129.0, 128.6, 127.4, 126.6, 
126.1, 125.3, 123.6, 51.7. 
General procedure for the azidation of 9-(bromomethyl)anthracene. 9-
(Chloromethyl)anthracene (10.8 mmol) was stirred in MeCN (30 mL) with NaN3 (14.4 mmol) 
and heated to reflux and stirred overnight104.  The reaction was cooled to room temperature, 
quenched with water, vacuum filtered, and recrystalized in MeOH / hexane (1:9).   
Equation 17  Azidation of 9-(bromomethyl)anthracene 
 
 9-(azidomethyl)anthracene (IX). Yellow needles, 49 % yield, mp = 83.4 – 84.0 oC; 
1H NMR (400 MHz, CDCl3) δ = 8.69 (s, 1H), 8.45 (d, J = 8.6 Hz, 2H), 8.14 (d, J = 8.6, 2H), 7.65 
– 7.61 (m, 2H), 7.58 – 7.54 (m, 2H), 5.51 (s, 2H).  13C NMR (100 MHz, DMSO-d6) δ = 130.9, 
130.2, 129.0, 128.6, 126.8, 126.4, 125.4, 124.0, 45.5. 
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2.2.1  “Click chemistry” 
General procedure for of 1,2,3-triazoles  by copper catalyzed Huisgen cycloaddition 
(“Click chemistry”).   
Route A.  The appropriate azide (V – IX, 0.6765 mmol) and alkyne (III – IV, 0.712 
mmol) were dissolved in DCM (5 mL) and CuSO4•5H2O (0.158 mmol) and sodium ascorbate 
(0.168 mmol) were added followed with by DCM (5 mL)105.  The reaction mixture was stirred 
overnight and quenched with a saturated solution of NH4Cl to remove copper salt, stirred open to 
the air for several hours, vacuum filtered, washed with diethyl ether, and heated at ~50 oC in a 
vacuum oven overnight.  If starting material were still present as indicated by 1H-NMR, the 
product was stirred for several hours in DCM, vacuum filtered, and heated at ~50 oC in a vacuum 
oven overnight.  Compounds X – XVI were synthesized by route A unless otherwise noted. 
Route B.  The appropriate azide (V – IX, 0.819 mmol) and alkyne III (0.717 mmol) were 
stirred in a 1:1 solution of t-butanol and water (30 mL) and CuSO4•5H2O (0.270 mmol) and so-
dium ascorbate (0.296 mmol) were added.  The reaction mixture was stirred overnight and 
quenched with a saturated solution of NH4Cl to remove copper salt, stirred open to the air for 
several hours, vacuum filtered, washed with diethyl ether, and heated at ~50 oC in a vacuum ov-
en overnight.  If starting material were still present as indicated by 1H-NMR, the product was 
stirred for several hours in DCM, vacuum filtered, and heated at ~50 oC in a vacuum oven over-
night.  Compounds X was synthesized by route B.   
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Equation 18  Copper catalyzed Huisgen cycloaddition of azide V - IX (A = CH or N) with alkynes III or IV. 
x = 0 - 2, y = 0 - 2, z = 1 - 2. 
 5-(4-((1-(quinolin-4-yl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophene-2-carbaldehyde (X).  Yellow solid, 90 % yield (10 % yield, route 
B), mp = 199.0 – 199.9 oC; 1H NMR (400 MHz, CDCl3) δ = 9.87 (s, 1H), 9.09 (d, J = 4.5 Hz, 
1H), 8.27 (d, J = 8.6 Hz, 1H), 8.15 (s, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.88 – 7.84 (m, 1H), 7.73 (d, 
J = 3.8 Hz, 1H), 7.69 – 7.65 (m, 3H), 7.56 (d, J = 4.5 Hz, 1H), 7.33 (d, J = 3.8 Hz, 1H), 7.12 (d, J 
= 8.6 Hz, 2H), 5.44 (s, 2H).  13C NMR (100 MHz, CDCl3) δ = 183.8, 159.1, 152.8, 150.9, 149.0, 
143.2, 141.1, 140.2, 139.5, 130.7, 129.6, 128.5, 127.8, 127.1, 125.6, 124.2, 122.9, 121.8, 117.1, 
115.6, 61.1.  HRMS: 413.1072 (obsd), 413.1067 (calcd) for  C23H16N4O2S (M + H)+. 
 5-(4-((1-(naphthalen-1-ylmethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophene-2-carbaldehyde (XI). Yellow solid, 47 % yield, mp = 169.9 – 
171.1 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.87 (s, 1H), 8.26 (s, 1H), 8.20 (d, J = 8.0, 1H), 
8.00 – 7.95 (m, 3H), 7.73 (d, J = 7.8, 2H) 7.63 (d, J = 3.4, 1H), 7.59 – 7.50 (m, 3H), 7.44 (d, J = 
5.4, 1H), 7.11 (d, J = 8.5, 2H), 6.11 (s, 2H), 5.18 (s, 2H).  13C NMR (100 MHz, DMSO-d6) δ = 
183.8, 159.1, 152.9, 142.6, 141.0, 139.5, 133.4, 131.5, 130.6, 129.1, 128.7,127.7, 127.3, 126.8, 
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126.2, 125.6, 125.3, 125.0, 124.1, 123.3, 115.6, 61.2, 50.8.  HRMS: 426.1266 (obsd), 426.1271 
(calcd) for C25H19N3O2S (M + H)+. 
 5-(4-((1-(2-(naphthalen-1-yl)ethyl)-1H-1,2,3-
triazol-4-yl)methoxy)phenyl)thiophene-2-carbaldehyde (XII). Yellow solid, 60 % yield, mp = 
172.7 – 173.7 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.88 (s, 1H), 8.26 (s, 1H), 8.14 (d, J = 7.8 
Hz , 1H), 8.02 (d, J = 3.8 Hz, 1H), 7.93 (d, J = 7.5 Hz, 1H), 7.81 – 7.75 (m, 3H), 7.65 (d, J = 3.8 
Hz, 1H), 7.59 -7.51 (m, 2H), 7.37 – 7.33 (m, 1H), 7.26 (d, J = 6.6 Hz, 1H), 7.13 (d, J = 8.6, 2H), 
5.20 (s, 2H), 4.72 (t, J = 6.5 Hz, 2H), 3.64 (t, J = 6.5 Hz, 2H).  13C NMR (100 MHz, DMSO-d6) δ 
= 183.7 159.4, 152.9, 142.3, 141.0, 139.5, 133.6, 133.4, 131.3, 128.7, 127.7, 127.3, 126.8, 126.3, 
125.8, 125.5, 125.3, 124.7, 124.1, 123.1, 115.3, 66.7, 50.7, 25.4.  HRMS: 440.1433 (obsd), 
440.1427 (calcd) for C26H21N3O2S (M + H)+. 
 5-(4-((1-(naphthalen-2-ylmethyl)-1H-1,2,3-
triazol-4-yl)methoxy)phenyl)thiophene-2-carbaldehyde (XIII).  yellow solid, 59 % yield, mp =  
157.0 – 157.9 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.87 (s, 1H), 8.08 (s, 1H), 8.37 (s, 1H), 
8.01 (s, 1H) 7.91 -7.84 (m, 4H), 7.75 (bs, 2H), 7.64 (s, 1H), 7.53 (s, 2H), 7.46 (s, 1H), 7.14 (bs, 
2H), 5.79 (s, 2H), 5.22 (s, 2H).  13C NMR (100 MHz, DMSO-d6) δ = 183.8, 159.1, 152.9, 143.7, 
142.7, 141.0, 139.5, 133.5, 132.7, 132.5, 128.5, 127.7, 127.6, 126.9, 126.6, 126.5, 125.8, 125.4, 
125.0, 124.2, 115.6, 61.3, 53.0.  HRMS: 426.1268 (obsd), 426.1271 (calcd) for C25H19N3O2S (M 
+ H)+. 
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 5-(4-(2-(1-(naphthalen-1-ylmethyl)-1H-1,2,3-
triazol-4-yl)ethoxy)phenyl)thiophene-2-carbaldehyde (XIV).  Orange solid, 99 % yield, mp =  
145.9 – 146.8 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.87 (s, 1H), 8.20 (d, J = 8.7, 1H), 8.00 – 
7.93 (m, 4H), 7.70 (d, J = 8.7, 2H), 7.62 (d, J = 6.3, 1H), 7.57 – 7.49 (m, 3H), 7.41 (d, J = 7.2, 
1H), 6.99 (d, J = 8.7, 2H), 6.06 (s, 2H), 4.26 (t, J = 6.4, 2H), 3.08 (t, J = 6.4, 2H). 13C NMR (100 
MHz, DMSO-d6) δ = 183.7, 159.4, 152.9, 140.9, 139.4, 128.9, 128.9,128.6, 127.7, 127.1, 126.7, 
126.1, 125.5, 125.1, 124.0, 123.3, 123.1, 115.3, 66.7, 50.7, 25.4.  HRMS: 440.1433 (obsd), 
440.1427 (calcd) for C26H21N3O2S (M + H)+. 
 5-(4-(2-(1-(2-(naphthalen-1-yl)ethyl)-1H-1,2,3-
triazol-4-yl)ethoxy)phenyl)thiophene-2-carbaldehyde (XV).  yellow solid, 81 % yield, mp =  
172.5 – 173.4 oC; 1H NMR (400 MHz, DMSO-d6 at 60 oC) δ = 9.88 (s, 1H), 8.09 (d, J = 7.9 Hz, 
1H), 7.96 (d, J = 3.8 Hz, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.83 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 
7.72 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 3.8 Hz, 1H), 7.57 – 7.50 (m, 2H), 7.37 (t, J = 7.6 Hz, 1H), 
7.30 (d, J = 6.7 Hz, 1H), 7.03 (d, J = 8.7 Hz, 2H), 4.70 (t, J = 7.3 Hz, 2H), 4.25 (t, J = 6.5 Hz, 
2H), 3.63 (t, J = 7.3 Hz, 2H), 3.08 (t, J = 6.5, 2H). 13C NMR (100 MHz, DMSO-d6) δ = 183.1, 
159.3, 152.7, 142.9, 140.8, 138.5, 133.4, 133.2, 131.1, 128.3, 127.4, 126.9, 126.4, 125.9, 125.3, 
125.1, 123.6, 122.9, 122.3, 115.2, 66.7, 49.6, 32.5, 25.2..  HRMS: 454.1589 (obsd), 454.1584 
(calcd) for C27H23N3O2S (M + H)+. 
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 5-(4-((1-(anthracen-9-ylmethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophene-2-carbaldehyde (XVI).  yellow solid, 93 % yield, mp =  206.8 – 
207.5 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9..86 (s, 1H), 8.74 (s, 1H), 8.61 (d, J = 8.6, 2H), 
8.16 (d, J = 7.8, 2H), 8.10 (s, 1H), 7.99 (d, J = 3.8, 1H), 7.70 – 7.55 (m, 7H), 7.05 (d, J = 8.3, 
2H), 6.67 (s, 2H), 5.09 (s, 2H).  13C NMR (100 MHz, DMSO-d6) δ = 183.8, 159.1, 152.9, 142.3, 
141.0, 139.5, 131.0, 130.3, 129.1, 127.7, 127.2, 125.7, 125.4, 125.3, 124.5, 124.1, 124.0, 115.5, 
61.0, 45.5.  HRMS: 476.1433 (obsd), 476.1427 (calcd) for C29H21N3O2S (M + H)+.   
General procedure for microwave synthesis of 1,2,3-triazoles  XVII and XVIII.   
Potassium hydroxide (8.71 mmol) was added to a solution of 2-naphthol (6.79 mmol) and 
the appropriate glycol (6.72 mmol) in 20 mL on n-butanol in an 80 mL microwave reaction vial.  
The reaction mixture was heated to 145 oC with 200 W and 200 maximum psi for 25 minutes.  
Next, the reaction was quenched with water (20 mL), extracted with ethyl acetate (20 mL x 3), 
washed with water (50 mL x 3), dried over magnesium sulfate, and concentrated in a rotary 
evaporator.  The oils were used without further purification 
The 2-naphthylalkoxytosylate was stirred in pyridine (10 mL) and cooled to 0 oC in an 
ice/water bath followed by addition of 7.17 mmol of tosylchloride.  The reaction was kept at 0 oC 
for 8 hours and then allowed to warm to room temperature and stir overnight.  The reaction was 
then quenched with 1M NH4Cl, extracted with 10 mL of ethyl acetate three times, washed with 
30 mL of water three times, dried over magnesium sulfate, and concentrated in a rotary evapora-
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tor.  The crude was then dissolved in DMF (10 mL) and NaN3 (4.59 mmol) was added to the so-
lution. The reaction mixture was stirred for 24 hours at room temperature, quenched with water 
(10 mL), dried over magnesium sulfate, and concentrated in a rotary evaporator.  The crude was 
then purified by flash column chromatography (silica gel) using ethyl acetate and hexane as elu-
ent.  The oils were used without further purification. 
The appropriate azide (0.742 mmol) and alkyne III (0.720 mmol) were dissolved in a 1:1 
solution of DCM / H2O (4 mL), CuSO4•5H2O (0.157 mmol) and sodium ascorbate (0.122 
mmol)105 in a 10 mL microwave reactor vial.  The reaction mixture was heated to 100 oC at 100 
W for 15 minutes.  NH4Cl was then added to the mixture and it was allowed to stir several hours 
opened to the air to remove copper salts. The contents were then vacuum filtered and washed 
with ether.  After drying overnight at ~50 oC in a vacuum oven, the crude was passed through a 
flach column (silica gel) using ethyl acetate and hexane as eluent and the fourth fraction was 
concentrated in a rotarty evaporator, dried overnight at ~50 oC in a vacuum oven, and used with-
out further purification. 
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Scheme 4  Synthesis of XVII and XVIII (x = 1 or 2) 
 5-(4-((1-(2-(2-(naphthalen-2-
yloxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)thiophene-2-carbaldehyde (XVII).  
yellow solid, 47 % yield, mp = 84.1 – 85.3 oC, 1H NMR (400 MHz, CDCl3) δ = 9.72 (s, 1H), 
7.74 (s, 1H), 7.63 – 7.56 (m, 4H), 7.41 (d, J = 7.1, 2H), 7.32 – 7.12 (m, 3H), 7.03 – 6.99 (m, 2H), 
6.82 (d, J = 7.1, 2H), 4.98 (bs, 2H), 4.46 (bs, 2H), 4.05 (bs, 2H), 3.84 (bs, 2H), 3.73 (bs, 2H).  
HRMS: 500.1644 (obsd), 500.1648 (calcd) for C35H31N7O3S (M + H)+.    
 5-(4-((1-(2-(2-(2-
(naphthalen-2-yloxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)thiophene-2-
carbaldehyde (XVIII).  Green-yellow waxy solid, 57 % yield, mp = ND (low melting waxy so-
lid); 1H NMR (400 MHz, DMSO-d6) δ = 9.76 (s, 1H), 7.78 (bs, 1H), 7.68 – 7.59 (m, 4H), 7.49 
(d, J = 8.6, 2H), 7.35 (bs, 1H), 7.25 (bs, 1H), 7.19 – 7.16 (m, 1H), 7.06 – 7.03 (m, 2H), 6.94 (d, J 
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= 8.6, 2H), 5.01 (bs, 2H), 4.44 (bs, 2H), 4.10 (bs, 2H), 3.76 (bs, 4H), 3.58 – 3.54 (m, 4H).  
HRMS: 544.1901 (obsd), 544.1890 (calcd) for C30H29N3O5S (M + H)+.   
Procedure for the synthesis of 1,2,3-triazoles  XXI.  
 Sodium carbonate (4.97 mmol) and 1,2-dibromoethane (24.93 mmol) was added to a stir-
ring solution of I in DMF and then heated to 90 oC and stirred overnight.  The reaction mixture 
was cooled to room temperature, quenched with water, and vacuum filtered.  The precipitate was 
purified by flash column chromatography (silica gel) using DCM as eluent to yield XIX.  XIX 
(1.62 mmol) was then dissolved in DMF (20 mL) and NaN3 (3.65 mmol) was added.  The reac-
tion mixture was then stirred overnight at room temperature and quenched with water.  The reac-
tion mixture was then vacuum filtered and purified by flash column chromatography (silica gel) 
and using DCM as eluent to yield XX. 
 To a stirring mixture of XX (0.824 mmol) and III (0.822 mmol) in a 1:1 solution of t-
butanol and water (15 mL) at room temperature was added copper(II) sulfate pentahydrate (0.191 
mmol) and sodium ascorbate (0.171 mmol).  The reaction mixture was stirred at room tempera-
ture for 24 hours, quenched with saturated NH4Cl and stirred open to the air for 6 hours.  The 
reaction mixture was then vacuum filtered and the precipitate was washed with DCM and then 
dried in a vacuum oven at ~50 oC. 
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Scheme 5  Synthesis of XXI 
 5-(4-(2-bromoethoxy)phenyl)thiophene-2-carbaldehyde (XIX) 
Yellow solid, 42 % yield, mp = 125.6 – 126.2 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.88 (s, 
1H), 8.01 (d, J = 3.8, 1H), 7.75 (d, J = 8.6, 2H), 7.64 (d, J = 3.8, 1H), 7.07 (d, J = 8.6, 2H), 4.39 
(t, J = 5.2, 2H), 3.83 (t, J = 5.2, 2H).  ESI-MS: m/z 311.1 (obsd), 311.0 (calcd) for (M+ +1). 
 5-(4-(2-azidoethoxy)phenyl)thiophene-2-carbaldehyde (XX) Yel-
low solid, 99 % yield, mp = 104.4 – 105.1 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.88 (s, 1H), 
8.01 (d, J = 3.9, 1H), 7.76 (d, J = 8.7, 2H), 7.65 (d, J = 3.9, 1H), 7.07 (d, J = 8.7, 2H), 4.24 (t, J = 
4.7, 2H), 3.68 (t, J = 4.7, 2H).  HRMS: 274.0650 (obsd), 274.0650 (calcd) for C13H12N3O2S (M + 
H)+.   
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 5-(4-((1-(2-(4-(5-formylthiophen-2-
yl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)thiophene-2-carbaldehyde (XXI)  Yel-
low solid, 80 % yield, mp = 195.1 – 197.0 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.87 (s, 1H), 
8.34 (s, 1H), 7.99 (d, J = 3.0, 2H), 7.75 – 7.69 (m, 4H), 7.64 – 7.60 (m, 2H) 7.14 (d, J = 8.7, 2H), 
7.00 (d, J = 8.7, 2H), 5.24 (s, 2H), 4.81 (bs, 2H), 4.47 (bs, 2H).  HRMS: 516.1026 (obsd), 
516.1046 (calcd) for C27H21N3O4S2 (M + H)+ 
2.2.2 Combilexin amidines 
General procedure for the oxidative cyclization towards amidines DB 2228, DB 
2229, DB 2261 – 2263, DB2266, DB 2268 – 2269, DB2292, and DB 2294.  Aldehydes X – 
XVIII (0.177 eq.) and 3,4-diaminobenzamidine hydrochloride (0.177 mmol) were stirred in 2-
methoxyethanol (20 mL).  p-Benzoquinone (0.180 mmol) was added as the oxidizing agent and 
the mixture was heated to reflux.  The reaction mixture was stirred for 2 days and then cooled to 
room temperature, and vacuum filtered.  The filtrate was concentrated using a rotary evaporator 
and the residue was mixed in acetone (10 mL), heated to reflux, and stirred for several hours.  
The reaction mixture was vacuum filtered while hot, washed with acetone, and the precipitate 
was dried in a vacuum oven over night at ~60 oC.  (Sometimes 1 mL of ice cold water was also 
used to wash the product if NMR showed NH4Cl was present.) 
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Equation 19  Oxidative cycloaddition of aldehydes X - XX (A = CH or N) with 3,4-diaminobenzamidine (ROH = 2-
methoxyethanol). 
 
 2-(5-(4-((1-(quinolin-4-yl)-1H-1,2,3-
triazol-4-yl)methoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydro-
chloride (DB 2228).  Violet solid, 49 % yield, mp = 206.8 – 221.2 oC dec.; 1H NMR (400 MHz, 
DMSO-d6) δ = 9.33 (s, 2H), 9.14 (d, J = 4.4 Hz, 1H), 9.01 – 8.97 (m, 3H), 8.23 (d, J = 7.6 Hz, 
1H), 8.10 (s, 1H), 8.00 (d, J = 3.2 Hz, 1H), 7.96 – 7.90 (m, 3H), 7.86 (d, J = 4.4 Hz, 1H), 7.78 – 
7.74 (m, 4H), 7.68 – 7.65 (m, 1H), 7.59 (d, J = 3.2 Hz, 1H), 7.24 (d, J = 8.0 Hz, 2H), 5.40 (s, 
2H).  HRMS: 543.1716 (obsd), 543.1710 (calcd) for C30H22N8OS (M + H)+.  Anal. Calcd for 
C30H22N8OS·HCl·1.75H20: C, 59.01; H, 4.37; N, 18.35.  Found: C, 59.16; H, 4.30; N, 18.13. 
 2-(5-(4-((1-(quinolin-4-yl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydrochloride (DB 
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2229).  Violet solid, 72 % yield, mp = 212.3 – 229.1 oC dec.; 1H NMR (400 MHz, DMSO-d6) δ 
= 9.32 – 8.95 (m, 4H), 8.27 (s, 1H), 8.15 (d, J = 8.1, 1H), 7.98 (bs, 1H), 7.94 (d, J = 7.8, 1H), 
7.81 (d, J = 8.1, 1H), 7.71 (d, J = 8.8, 2H), 7.68 (bs, 2H), 7.58 – 7.52 (m, 4H), 7.38 – 7.34 (m, 
2H), 7.27 – 7.25 (m, 1H), 7.13 (d, J = 8.8, 2H), 5.20 (s, 2H), 4.73 (t, J = 7.4, 2H), 3.65 (t, J = 
7.34, 2H).  HRMS: 570.2076 (obsd), 570.2071 (calcd) for C33H27N7OS (M + H)+.  Anal. Calcd 
for C33H27N7OS·HCl·0.55H2O: C, 64.34; H, 4.76; N, 15.92.  Found C, 64.34; H, 4.69; N, 15.92. 
 2-(5-(4-((1-(naphthalen-1-ylmethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydrochloride 
(DB2261).  Brown solid, 78 % yield, mp = 226.8 – 235.1 oC dec.; 1H NMR (400 MHz, DMSO-
d6) δ =  9.34 (s, 1H), 9.29 (s, 1H), 8.93 (bs, 3H), 8.26 (s, 1H), 8.21 (d, J = 8.2 Hz, 1H), 8.16 (s, 
1H), 7.99 (d, J = 8.8 Hz, 2H), 7.95 – 7.93 (m, 1H), 7.80 (d, J = 7.2 Hz, 1H), 7.69 – 7.79 (m, 3H), 
7.64 – 7.51 (m, 4H), 7.45 (d, J = 6.8 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 6.12 (s, 2H), 5.17 (s, 2H).  
HRMS: 556.1920 (obsd), 556.1914 (calcd) for C32H25N7OS (M + H)+.  Anal. Calcd for 
C32H25N7OS·HCl·1.68H2O: C, 61.75; H, 4.76; N, 15.75.  Found C, 61.68; H, 4.65; N, 15.65. 
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 2-(5-(4-((1-(naphthalen-2-ylmethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydrochloride 
(DB2262).  Brown solid, 68 % yield, mp = 216.0 – 220.1 oC dec.; 1H NMR (400 MHz, DMSO-
d6) δ = 9.28 (s, 2H), 8.95 (s, 2H),  8.37 (s, 1H), 8.09 (bs, 1H), 7.94 – 7.88 (m, 4H), 7.85 (s, 1H), 
7.74 – 7.64 (m, 4H), 7.56 – 7.52 (m, 4H), 7.46 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 8.6 Hz, 2H), 5.80 
(s, 2H), 5.22 (s, 2H).  HRMS: 556.1920 (obsd), 556.1914 (calcd) for C32H25N7OS (M + H)+.  
Anal. Calcd for C32H25N7OS·HCl·2.46H2O: C, 60.39; H, 4.90; N, 15.41.  Found C, 60.06; H, 
4.55; N, 15.17. 
 2-(5-(4-methoxyphenyl)thiophen-2-yl)-1H-
benzo[d]imidazole-6-carboximidamide hydrochloride (DB2263).  Brown solid, 80 % yield, mp = 
> 250 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.33 (s, 2H), 9.02 (s, 2H), 8.16 (s, 1H), 8.01 (bs, 
2H), 7.73 – 7.68 (m, 4H), 7.55 (d, J = 3.4 Hz, 1H), 7.04 (d, J = 8.7 Hz, 2H), 3.81 (s, 3H).  
HRMS: 349.1123 (obsd), 349.1118 (calcd) for C19H16N4OS (M + H)+.  Anal. Calcd for 
C19H16N4OS·HCl·0.80H2O: C, 57.15; H, 4.70; N, 14.03.  Found C, 56.80; H, 4.56; N, 14.38. 
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 2-(5-(4-((1-(anthracen-9-ylmethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydrochloride 
(DB2266).  Brown solid, 78 % yield, mp  > 250 oC; 1H NMR (400 MHz, DMSO-d6) = 9.39 (s, 
2H), 9.11 (s, 2H), 8.73 (s, 1H), 8.62 (d, J = 8.6 Hz, 2H), 8.16 – 8.13 (m, 4H), 8.04 (bs, 1H), 7.75 
– 7.63 (m, 7H), 7.56 (t, J = 7.5 Hz, 2H), 7.52 (d, J = 3.8 Hz, 1H), 7.05 (d, J = 8.4 Hz, 2H), 6.68 
(s, 2H), 5.08 (s, 2H).  HRMS: 606.2076 (obsd), 606.2071 (calcd) for C36H27N7OS (M + H)+.  
Anal. Calcd for C36H27N7OS·HCl·1.52H2O: C, 64.58; H, 4.67; N, 14.64.  Found C, 64.35; H, 
4.44; N, 14.66. 
 2-(5-(4-(2-(1-(2-(naphthalen-1-yl)ethyl)-1H-1,2,3-triazol-
4-yl)ethoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydrochloride 
(DB2268).  Grey solid, 77 % yield, mp = >250 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.40 (s, 
1H), 9.35 (s, 1H), 9.09 (s, 1H), 8.18 (s, 1H), 8.12 – 8.02 (m, 3H), 7.95 – 7.92 (m, 2H), 7.79 (d, J 
= 7.8 Hz, 2H), 7.70 – 7.64 (m, 4H), 7.59 – 7.51 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 7.28 (d, J = 7.0 
Hz, 1H), 7.03 (d, J = 8.5 Hz, 2H), 4.68 (t, J = 7.2 Hz, 2H), 4.22 (t, J = 6.2 Hz, 2H), 3.61 (t, J = 
7.2 Hz, 2H), 3.07 (t, J = 6.4 Hz, 2H).  HRMS: 584.2233 (obsd), 584.2227 (calcd) for 
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C34H29N7OS (M + H)+.  Anal. Calcd for C34H29N7OS·HCl·1.21H2O: C, 63.61; H, 5.09; N, 15.27.  
Found C, 63.29; H, 4.79; N, 15.61. 
 2-(5-(4-(2-(1-(naphthalen-1-ylmethyl)-1H-1,2,3-
triazol-4-yl)ethoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-6-carboximidamide hydrochlo-
ride (DB2269).  Purple solid, 64 % yield, mp = 238.6 – 242.9 oC dec.; 1H NMR (400 MHz, DM-
SO-d6) δ = 9.39 – 9.33 (m, 2H), 9.07 (s, 2H), 8.21 – 8.17 (m, 2H), 8.06 – 7.94 (m, 5H), 7.79 (d, J 
= 8.4 Hz, 1H), 7.70 (s, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.61 – 7.50 (m, 4H), 7.42 – 7.41 (m, 1H), 
6.98 (d, J = 8.0 Hz, 2H), 6.07 (s, 2H), 4.25 (t, J = 6.6 Hz, 2H), 3.08 (t, J = 6.6 Hz, 2H).   HRMS: 
570.2076 (obsd), 570.2071 (calcd) for C33H27N7OS (M + H)+.  Anal. Calcd for 
C33H27N7OS·HCl·0.79H2O: C, 63.89; H, 4.81; N, 15.81.  Found C, 63.79; H, 4.69; N, 15.89. 
O
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 2-(5-(4-((1-(2-(2-(naphthalen-2-yloxy)ethoxy)ethyl)-
1H-1,2,3-triazol-4-yl)methoxy)phenyl)thiophen-2-yl)-1H-benzo[d]imidazole-5-carboximidamide 
hydrochloride (DB2292).  Brown solid, 82 % yield, mp = >250 oC; 1H NMR (400 MHz, DMSO-
d6) δ 9.30 (bs, 2H), 8.94 (s, 2H), 8.24 (s, 1H), 8.16 (s, 1H), 7.97 (d, J = 3.5 Hz, 1H), 7.78 – 7.72 
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(m, 4H), 7.67 – 7.63 (m, 3H), 7.51 (d, J = 3.7 Hz, 1H), 7.44 – 7.40 (m, 1H), 7.34 – 7.30 (m, 1H), 
7.26 (bs, 2H), 7.12 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 8.3 Hz, 2H), 5.15 (s, 2H), 4.60 (t, J = 4.5 Hz, 
2H), 4.18 (bs, 2H), 3.93 (t, J = 4.5 Hz, 2H), 3.82 (bs, 2H).  HRMS: 630.2287 (obsd), 630.2269 
(calcd) for C35H31N7O3S (M + H)+.  Anal. Calcd for C35H31N7O3S·HCl·0.40H2O: C, 62.43; H, 
4.91; N, 14.56.  Found C, 62.27; H, 4.90; N, 14.75. 
O
N
N
N
O
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HN N
NH
H2N
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3
 2-(5-(4-((1-(2-(2-(2-(naphthalen-2-
yloxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)thiophen-2-yl)-1H-
benzo[d]imidazole-5-carboximidamide hydrochloride (DB2294).  Brown solid, 68 % yield, mp = 
>250 oC; 1H NMR (400 MHz, DMSO-d6) δ = 9.33 (bs, 2H), 9.00 (s, 2H), 8.23 (s, 1H), 8.00 (s, 
1H), 7.88 (d, J = 3.1 Hz, 1H), 7.80 – 7.77 (m, 5H), 7.65 – 7.61 (m, 3H), 7.53 (d, J = 3.3 Hz, 1H), 
7.42 – 7.39 (m, 1H), 7.33 – 7.29 (m, 1H), 7.24 (s, 1H), 7.14 (d, J = 8.9 Hz, 1H), 7.09 (d, J = 8.5 
Hz, 2H), 5.17 (s, 2H), 4.56 (bs, 2H), 4.17 (bs, 2H), 3.85 (bs, 2H), 3.75 (bs, 2H), 3.58 (bs, 4H).  
HRMS: 674.2549 (obsd), 674.2540 (calcd) for C37H35N7O4S (M + H)+.  Anal. Calcd for 
C37H35N7O4S·HCl·0.50H2O: C, 61.79; H, 5.19; N, 13.63.  Found C, 61.37; H, 5.09; N, 14.06. 
2.3 DAPI boron derivatives 
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General procedure for the synthesis of diazaboroles.  Toluene (3 mL) was added to a 
10 mL microwave reaction vessel with the appropriate o-phenylenediamine (1.648 mmol) and 
the phenyl boronic acid (1.647 mmol).  The reaction vessel was held upright on a stir plate and 
allowed to stir for several minutes.  The reaction vessel was then transferred to the microwave 
reactor and heated to 115 oC at 200 W for 10 minutes.  The contents of the reaction vessel were 
vacuum filtered and the precipitate was dried overnight in a vacuum oven at ~50 oC.   Com-
pounds XXIII was recrystallized in toluene and hexane.  Compounds XXIV – XXIX were re-
crystallized in toluene and DCM.  Compounds XXXI – XXXII were recrystallized in toluene.  
Equation 20  Synthesis of benzo[d]1,3,2-diazaboroles 
 
 5-bromo-2-(4-bromophenyl)-2,3-dihydro-1H-
benzo[d][1,3,2]diazaborole (XXIII).  Orange solid, 64 % yield, mp 180.8 – 181.2 oC;   1H NMR 
(400 MHz, DMSO-d6) δ ppm 9.38 (br. s., 2H) 7.83 (m, J = 8.2 Hz, 2H) 7.66 (m, J = 8.2 Hz, 2H) 
7.18 (s, 1H) 6.89 - 7.08 (m, 2H);  13C NMR (100 MHz, DMSO-d6) δ ppm 138.2, 135.9, 134.9, 
130.5, 123.0, 120.4, 112.9, 111.7, 109.7.  11B NMR (128 MHz, DMSO-d6) δ ppm 18.41.  
HRMS: 348.9140 (obsd), 348.9153 (calcd) for C12H8N2BBr2 (M - H)-.   
 4-(5-bromo-1,3-dihydro-2H-benzo[d][1,3,2]diazaborol-2-
yl)benzonitrile (XXIV). Light brown solid, 91 % yield, mp = 179.0 – 179.8 oC;  1H NMR (400 
MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 9.82 (s, 1H), 8.10 (d, J = 7.5 Hz, 2H), 7.93 (d, J = 7.5 Hz, 
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2H), 7.47 (s, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H);  13C NMR (100 MHz, 
DMSO-d6) δ ppm 140.6, 136.5, 133.6, 131.2, 123.4, 120.2, 118.4, 113.7, 111.7, 111.4, 99.8.  11B 
NMR (128 MHz, DMSO-d6) δ ppm = 18.59.  HRMS: 296.00 (obsd), 296.00 (calcd) for 
C13H9BBrN3 (M - H)-.  
 2-(4-cyanophenyl)-2,3-dihydro-1H-benzo[d][1,3,2]diazaborole-
5-carbonitrile (XXVI).  Tan solid, 87 % yield, mp = 224.2 – 225.1 oC;   1H NMR (400 MHz, 
DMSO-d6) δ ppm 9.47 - 9.62 (m, 2H), 8.07 (d, J = 7.5 Hz, 2H), 7.91 (d, J = 7.5 Hz, 2H), 7.23 (s, 
1 H), 7.03 (q, J = 8.2 Hz, 2H);  13C NMR (100 MHz, DMSO-d6) δ ppm 138.1, 135.8, 133.5, 
131.1, 120.7, 118.5, 113.2, 112.0, 111.4, 110.0. 11B NMR (128 MHz, DMSO-d6) δ ppm = 18.44  
 2-(4-cyanophenyl)-2,3-dihydro-1H-
benzo[d][1,3,2]diazaborole-5-carboxylic acid (XXVII), l. pink, 41 % yield, mp > 300 oC;  1H 
NMR (400 MHz, DMSO-d6): δ ppm 12.31 (bs, 1H), 9.78 (s, 1H), 9.61 (s, 1H), 8.09 (d, J = 7.3 
Hz, 2H), 7.93 (d, J = 6.5 Hz, 2H), 7.71 (s, 1H), 7.59 (d, J = 7.7 Hz, 1H), 7.16 ppm (d, J = 8.2 Hz, 
1H).  13C NMR (DMSO-d6, 100MHz): δ ppm = 167.6, 140.5, 136.1, 133.5, 131.1, 120.9, 120.6, 
118.5, 111.8, 111.5, 110.1. 11B NMR (128 MHz, DMSO-d6) δ ppm = 18.58.  HRMS: 262.0782 
(obsd), 262.0781 (calcd) for C14H10BN3O2 (M - H)-.   
 4-(5-cyano-1,3-dihydro-2H-benzo[d][1,3,2]diazaborol-2-
yl)benzoic acid (XXVIII), tan, 96 % yield, mp = 145.8 – 146.5 oC;  1H NMR (DMSO-d6 
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,400MHz): δ ppm 12.91 (bs, 1H), 9.92 (s, 1H), 9.75 (s, 1H), 8.02 (s, 4H), 7.44 (s, 1H), 7.31 (d, J 
= 7.5 Hz, 1H), 7.23 ppm (d, J = 7.5 Hz, 1H).  13C NMR (DMSO-d6, 100MHz): δ = 167.3, 141.2, 
137.1, 133.7, 131.8, 128.7, 123.7, 120.8, 114.0, 111.7, 100.0.  11B NMR (128 MHz, DMSO-d6) δ 
ppm = 18.45.  HRMS: 262.0790 (obsd), 262.0782 (calcd) for C14H10BN3O2 (M - H)-. 
H
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N
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 2-(4-carboxyphenyl)-2,3-dihydro-1H-
benzo[d][1,3,2]diazaborole-5-carboxylic acid (XXIX), l. pink, 30 % yield mp > 300 oC;  1H 
NMR (DMSO-d6 ,400MHz): d = 12.30 (bs, 1H), 9.70 (bs, 1H), 9.53 (bs, 1H), 8.02 (s, 4H), 7.69 
(s, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.14 ppm (d, J= 7.7 Hz, 1H).  13C NMR (DMSO-d6, 100 MHz): 
δ = 168.2, 167.4, 141.2, 136.7, 133.6, 131.6, 128.7, 121.3, 121.0, 112.2, 110.5.  11B NMR (128 
MHz, DMSO-d6) δ ppm = 18.41. HRMS: 281.0734 (obsd), 281.0734 (calcd) for C14H10O4N2B 
(M - H)-  
4-(1,3-dihydro-2H-benzo[d][1,3,2]diazaborol-2-yl)benzoic acid 
(XXXI), tan, 83 % yield mp = > 250 oC,.  1H NMR (DMSO-d6, 400MHz): d = 12.47 (bs, 1H), 
9.30 (bs, 1H), 8.00 – 7.98 (m, 4H), 7.08 (bs, 2H), 6.84 (bs, 2H).  13C NMR (DMSO-d6, 100MHz): 
δ = 167.5, 137.0, 134.1, 133.4, 128.6, 128.1, 118.5, 111.0.  11B NMR (128 MHz, DMSO-d6) δ 
ppm = 18.30.  HRMS: 237.0836 (obsd), 237.0841 (calcd) for C13H10O2N2B (M - H)- 
2-(4-fluorophenyl)-2,3-dihydro-1H-benzo[d][1,3,2]diazaborole (XXXII) 
tan, 83 % yield, mp = > 250 oC ,.  1H NMR (DMSO-d6, 400MHz): d = 9.13 (s, 1H), 7.94 (t, J = 
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6.1, 2H), 7.28 – 7.24 (m, 2H), 7.04 (bs, 2H), 6.81 (bs, 2H). 13C NMR (DMSO-d6, 100MHz): δ = 
137.1, 135.6, 135.5, 118.3, 115.0, 114.8, 110.8.  11B NMR (128 MHz, DMSO-d6) δ ppm = 18.91.  
11B NMR (128 MHz, CDCl3) δ ppm = 28.63.  HRMS: 211.0843 (obsd), 211.0847 (calcd) for 
C12H9N2BF (M - H)- 
Procedure for the synthesis of 4-(5-carbamimidoyl-1,3-dihydro-2H-
benzo[d][1,3,2]diazaborol-2-yl)benzoic acid.  Anhydrous ethanol (3 mL) and anhydrous tolu-
ene (3 mL) was added to a 10 mL microwave reaction vessel with 3,4-diaminobenzamidine hy-
drochloride (1.07 mmol) and the 4-carboxyphenyl boronic acid (2.14 mmol).  The reaction vessel 
was held upright on a stir plate and allowed to stir for several minutes.  The reaction vessel was 
then transferred to the microwave reactor and heated to 115 oC at 200 W for 30 minutes.  The 
contents of the reaction vessel were vacuum filtered and the precipitate was placed in a 10 mL 
microwave reaction vessel.  Five mL of anhydrous ethanol was placed in the microwave reaction 
vessel and heated to 70 oC at 200 W for 1 minute, then vacuum filtered while hot.  The precipi-
tate was then placed in the microwave reaction vessel, 5 mL of anhydrous ethanol was added, 
and the vessel was heated to 70 oC at 200 W for 1 minute, then vacuum filtered while hot.  The 
precipitate was collected into the microwave reaction vessel again and heated to 70 oC for w mi-
nute in anhydrous ethanol and vacuum filtered.  After the third microwave heating and vacuum 
filtering, the precipitate was dried overnight in a vacuum oven at ~ 50 oC. 
Equation 21  Synthesis of XXX 
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4-(5-carbamimidoyl-1,3-dihydro-2H-
benzo[d][1,3,2]diazaborol-2-yl)benzoic acid hydrochloride (XXX), tan, 52 % yield mp > 300 
oC,;  1H NMR (DMSO-d6 ,400MHz): d = 13.02 (bs, 1H), 9.96 (s, 1H), 9.83 (s, 1H), 9.14 (s, 2H), 
8.87 (s, 2H), 8.08 (d, J = 7.8 Hz 2H), 8.01 (d, J = 7.8 Hz 2H), 7.56 (s 1H), 7.43 (d, J = 8.2 Hz 
1H), 7.26 ppm (d, J = 8.2 Hz, 1H).  13C NMR (DMSO-d6, 100MHz): δ ppm = 167.4, 166.3, 
142.2, 137.1, 133.8, 131.9, 128.7, 119.8, 117.6, 111.0, 110.6   11B NMR (128 MHz, DMSO-d6) δ 
ppm = 18.48.  HRMS: 281.1199 (obsd), 281.1204 (calcd) for C14H13BN4O2 (M - H)-.  Anal. 
Calcd for C14H13BN4O2·3.7HCl: C, 40.95; H, 3.50; N, 13.54.  Found C, 40.52; H, 4.06; N, 13.50. 
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3     RESULTS and DISCUSSION 
3.1 DB818 combilexins 
3.1.1 Chemistry 
Synthesis of the DB 818 fragment I began by Suzuki coupling of 5-bromothiophen-2-
carbaldehyde with the corresponding boronic acid (4-hydroxyphenylboronic acid).  Sodium car-
bonate could be used as the base without significant decrease in yield; however, potassium car-
bonate was primarily used since a modest increase in yield was noted (Scheme 4).  Initial synthe-
sis of I (Figure 14) used THF (tetrahydroxyfuran) as solvent and 
Pd(PPh3)4 as catalyst following the method of S. Costa et al.106 re-
sulting in low yields between 13 – 20 %.  Using the M. Bandini et al. method107 of DME (1,2-
dimethoxyethane) / EtOH (ethanol) / 2N Na2CO3 (4:2:3) with PdCl2(PPh3)2 as catalyst resulted 
in significant yield increase to 50 %.  There are 4 possible reasons for the yield increase: 1) The 
solvent mixture has a higher boiling point than THF (b.p. 66 oC), 2) DME and EtOH solubilizes 
the starting materials and catalyst more compared to THF, 3) DME and EtOH are miscible in 
water putting more of the base in solution and 4) PdCl2(PPh3)2 was a  better catalyst compared to 
Pd(PPh3)4.  Use of Pd(PPh3)4 with the aforementioned reaction conditions resulted in a 10 – 15% 
yield decrease; therefore, only PdCl2(PPh3)2 was used in the synthesis of I.  PdCl2(PPh3)2 may be 
a better catalyst most likely because of its square planar geometry – Pd(PPh3)4 has a tetrahedral 
geometry.  However, palladium catalysis is a complex process that is also dependent on sub-
strates involved and solvents used and exploration of these factors is outside the scope of this 
dissertation.  After exploring the patents of Japan Tobacco Inc.108 and Peter Maccallum Cancer 
Figure 14  Structure of com-
pound I 
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Institute109, it was discovered that the best solvent mixture is MeOH (methanol) / H2O (1:1) us-
ing PdCl2(PPh3)2 as catalyst and either Na2CO3 or K2CO3 as base typically gave higher yields.  
Under these conditions, 75 % yields were obtained (Scheme 6).  This may be again because of 
the increased solubility the starting materials have in methanol.  Microwave synthesis can also be 
used to make I and II with higher yields (90 % and 99 %, respectively using the same procedures 
in section 2 Experimentals).  However, that method was not used often due to the need for large 
scale synthesis and the limitation of scale with microwave reactors. 
Alkylation of I to yield III proceeded readily with propargyl bromide and either Na2CO3 
or K2CO3 as base in DMF with heating to 80 oC producing yields of 99 %.  Heating at higher 
temperatures dramatically decreased product yield (65%).  It must be noted that it is not recom-
mended that synthesis of III be carried out in a microwave reactor.  Above 90 oC, propargyl 
bromide (b.p. 89 oC) can dramatically raise the pressure of the reaction vessel to over 200 psi 
prompting automatic shutoff by the microwave reac-
tor’s safety control.  Synthesis of IV by alkylating I 
was not as straightforward.  Various substrates were 
used in attempt to make IV including bromo-, iodo-, 
and tosyl- butyne.  It was found that only but-3-yn-1-
yl trifluoromethanesulfonate could be used for alkyl-
 
DB 818     DB 818 fragment 
Figure 15  Structures of DB 818 and DB 818 fragment 
 
II 
III 
IV 
Figure 16  Structures of molecules II, III, IV. 
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ation.  Unfortunately, but-3-yn-1-yl trifluoromethanesulfonate could only be made in small quan-
tities; attempts to scale up this synthesis resulted in dramatically decreased yield.  Consequently, 
the compound was made in small batches.
Scheme 6  Synthesis of Combilexin compounds (x = 0 – 3, y = 0 – 2, z = 1 – 2) 
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Initially, to yield aldehyde X (Figure 17), “Click chemistry” was done in t-BuOH / H2O 
(1:1) with 10 % CuSO4 and 10 % NaAsc (sodium ascorbate) as done in the lab of K. B. 
Sharpless 69.  However, by following the method of  Lee et al.105 – dichloromethane (DCM) / 
H2O (1:1) with 10 - 20 % CuSO4 and 15 % NaAsc – yields were increased and reaction time de-
creased.  For example, for the synthesis of X, yields increased from 45 % to 90 % and reaction 
time decreased from 24 hours to overnight.  This methodology was employed for X – XVI.  The 
“Click chemistry” involving the long glycolic chain naphthalenes with III using conventional 
Figure 17  Structures of aldehyces X - XVIII 
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methods resulted in yields of less than 20 % for XVII and XVIII.  Fortunately, using microwave 
irradiation produced yields of 47 % for XVII and 57 % for XVIII.   
The azide and alkyne sub-
strates were soluble in DCM, pre-
sumably resulting in the higher yields; even though the catalyst is insoluble in both DCM and 
water.  Catalysis most likely is occurring at the phase boundary110.  The DCM / H2O mixture is 
not optimal for all “Click chemistry” reactions.  “Click chemistry” using the DCM / H2O solvent 
system on III and XX to yield XXI (Figure 18) resulted in no reaction; even though, both III and 
XX are soluble in DCM.  However, by changing the solvent system to t-BuOH / H2O (1:1), 
yields of 99 % were achieved.  An explanation for this result would require more study which is 
outside the scope of this dissertation.  In all cases, synthesis of the 1,2,3-triazole can be con-
firmed by location of a singlet between 7.7 – 9.4  ppm111 in the 1H-NMR spectrum (DMSO-d6 as 
solvent) which represents the aromatic CH signal at the 5 position of the 1,2,3-triazole. 
To synthesize the final amidine compounds (Figure 19), it was found that it is more facile 
to synthesize 3,4-diaminobenzimidamide hydrochloride by the Pinner reaction and then do the 
oxidative cycloaddition with the aldehyde reactant using p-benzoquinone as the oxidizing agent 
in anhydrous ethanol (see Scheme 7).  This method is preferable to the alternative of synthesiz-
ing the cyano-benzimidazole precursor by oxidative cycloaddition with the aldehyde substrate 
and 4-cyanophenylene diamine and then using the Pinner reaction to yield the final amidine 
products because the cyano-benzimidazole precursors tend to have low solubility in ethanol, re-
sulting in the Pinner reaction taking up to several weeks38 (Scheme 7).  An additional benefit of 
this route is that purification is simpler after using the preferred method of oxidative 
Figure 18  Structure of aldehyde XXI 
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cycloaddition amidine-benzimidazole synthesis versus cyano-benzimidazole synthesis because 
73 
acetone can be used to wash away unreacted aldehyde, p-benzoquinone, and p-hydroxyquinone 
74 
by-product.  The amidine hydrochloride salts are insoluble in acetone whereas the cyano-
75 
benzimidazole is soluble in acetone and other purification methods would have to be sought.  
76 
This leads to one purification method for this series of compounds instead of development of dif-
Figure 19  Structures of Combilexins 
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ferent purification methods for each compound individually.  Moreover, the Pinner reaction on a 
cyano-benzimidazole precursor may result in unwanted amide or unreacted imidate ester side 
products which are not easily removed.  By already having a pure amidine source in 3,4-
diaminobenzimidamide hydrochloride, one avoids those pitfalls.  p-Benzoquinone was found to 
be the best oxidizing agent for benzimidazole synthesis.  Sodium perborate76 and cobalt(II) hy-
droxide79 were also explored as oxidizing agents.  These inorganic salts proved difficult to re-
move from the final product because both inorganic salts and final products (hydrochloride salt 
and free base) were water soluble.  Cobalt(II) hydroxide was especially difficult to remove be-
cause it apparently formed complexes with the amidine. 
 
Scheme 7  Synthesis of final product by oxidative cycloaddition of 3,4-diaminobenzonitrile with an aldehyde followed by 
the Pinner reaction (top) and synthesis of the final product by oxidative cycloaddition 3,4-diaminobenzamidine hydro-
chloride with an aldehyde 
3.1.2 DB 818 Analogues DNA Binding and T. b. r. Results 
The strong minor groove binding of DB 818 results from its shape complementarity with 
the groove, the electrostatic interaction of the amidines, and the bifurcated hydrogen bonding of 
the terminal amidines to AT base pairs38.  It is likely that eliminating an amidine would decrease 
AT affinity; however, it was hypothesized that the isohelicty of the DB 818 fragment and the 
added energetics of intercalation of the appended polynuclear aromatic rings of the combilexins 
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may compensate for the loss of one amidine unit.  To explore the effect of the loss of one 
amidine group, DB 2263 (Figure 19) was synthesized as a control.  DB 2263 is DB 818 with a 
methoxy group on the phenyl ring in lieu of an amidine.  The methoxy group is expected to have 
limited interference in the minor groove.  The ∆Tm for DB 2263 on the Drew-Dickerson 
dodecamer (5’-GCGAAATTTCGTCTCCGAAATTTCGC-3’) is 10.1 oC, about half of the ∆Tm 
for DB 818.  It is hypothesized that some of the affinity loss can be offset by the binding of the 
intercalator and perhaps by the triazole hydrogen bonding.  
Additionally, preliminary molecular modeling study using AutoDock in Sybyl (Figure 
20) showed that in addition to minor groove binding and intercalation, there is the potential for 
hydrogen bonding with the 1,2,3-triazole moiety of the combilexins.  These preliminary studies 
lead us to conclude that additional hydrogen bonding motifs have the potential to help offset the 
loss of one amidine unit.  
                      
A        B       C 
Figure 20  Graphics of molecular modeling done with Sybyl using AutoDock on d(CGCGAATTCGCG) DNA.  A) DB 818 
bound to the minor groove and naphthalene intercalating.  B & C) DB 2229 and naphthalene linked together (shown from 
different perspectives). 
DB 818 shows strong DNA minor groove binding at AAATTT tracts; hence, two 
tives, DB 2228 and 2229, were initially evaluated wit
guide the direction of the project (Table 
for A3T3 (DB 2228, 5.0 oC; DB 2229
Since both DB 2228 and DB 2229
clear what causes the difference in their affinities.
Table 2  ∆Tm values for DB 2228 and 2229 to A
∆Tm comparisons of DB 2261
finities for these compounds compared to
3).  These results show that both amidines are 
one substantially affects binding.  
ing motifs – the 1,2,3-triazole – to compensate for the loss of one amidine was not supported by 
the data.  Moreover, the intercalating unit did not aid in compensating for the loss of an amidine 
unit either.  The alterations made to the 
h A3T3 and A4T4 DNA sequences to 
2).  Compared to DB 2229, DB 2228 had a higher 
, 2.9 oC) and A4T4 (DB 2228, 4.9 oC; DB 2229
 can interact with DNA by multiple binding modes, it is u
 
3T3 and A4T4 DNA sequences with a salt concentration of 100 mM.
-63, 2266, and 2269 binding to AATT showed reduced 
 the control, DB 2263, which is the best binder (Table 
quite important to DNA binding and the loss of 
However, the hypothesis of adding additional hydrogen bon
DB 818 fragment were deleterious to DNA binding, but 
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DB 818 deriva-
help 
∆Tm 
, 3.4 oC).  
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we also hypothesized that it is possible that the linkers were not long enough to allow hydrogen 
bonding interactions with the 1,2,3-triazole, effective intercalation, and minor groove binding.   
Table 3  ∆Tm values for DB compounds to A2T2 DNA sequence with a salt concentration of 50 mM.   
 
∆Tm  (oC)
AATT
2261 1.4
2262 1.6
2263 3.9
2266 0.5
2269 2.5
DB
N
N
N
O
S
N
HN
NH
H2N
HCl
N
N
N
O
S N
HN
NH
H2N HCl
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To explore the above hypothesis, DB 2292 and 2294 were synthesized.  To evaluate bind-
ing of all combilexins, the hairpin Drew-Dickerson dodecamer was once again employed (in 10 
mM NaCl, 10 mM Cacodylic  acid, 1 mM EDTA, pH 6.25 [(DB):(DNA) = 2:1]).  Analysis of 
the ∆Tm data in Table 4 shows that longer linkers do not significantly improve ∆Tm values (Ta-
ble 4).  The longer linkers do not significantly improve the binding in reference to the control DB 
2263 and the parent compound DB 818.  This does not support the previous hypothesis that the 
lower ∆Tm’s were due to the linkers not being long enough to allow intercalation and H-bonding.  
It is clear that a number of additional molecules with varying lengths of both linkers – the one 
between the triazole and the DB 818 fragment and the one between the triazole and the 
intercalator unit – must be made and evaluated in order to fully test the original combilexin hy-
pothesis. 
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However, in vitro T. b. r. testing showed that there is biological activity for this series of 
83 
compounds despite the lower ∆Tm data.  Biological activity was evaluated by exposing T. b. r. 
parasites to DB compounds and determining the concentration of compound needed to kill 50 % 
of the parasites (IC50).  The best biological activities were seen in the compounds that had one 
methylene carbon adjacent to the DB 818 fragment: DB 2262 (IC50 = 0.26 µmol), DB 2229 (IC50 
= 0.46 µmol), DB 2266 (IC50 = 0.59 µmol), DB 2261 (IC50 0.69 µmol).  It is important to note 
that these compounds range from 13 to 35 times more active than the control monoamidine 
DB2263 which demonstrates the importance of the triazole linked aryl unit for T. b. r. activity in 
these combilexins.  DB 2292 and 2294 are analogues of the compound with the best biological 
activity. Unfortunately, biological data for DB 2292 and 2294 is not yet available. 
Table 4  Cytotoxicity and ∆Tm (in 10 mM NaCl, 10 mM Cacodylic  acid, 1 mM EDTA, pH 6.25 
[(DB):(DNA) = 2:1]) ranked in order of lowest IC50 value to highest.  Red = sub-micromolar IC50 values.  
Blue = best two DB compounds with the highest ∆Tm values (excluding control DB 2263). 
O
N
NN
O
S
N
NH
NH2
HN
HCl
yz
x
 
  Linker ΔTm  (
o
C)
a 
T. b. r.
b 
DB Intercalator x y z 
5’-GCGAAATTTCGTC 
3’-CGCTTTAAAGCCT IC50 (μmol) 
cytotox 
IC50 
(μmol) 
SI 
2262 2-naphthalene 0 1 1 4.5 0.26 97.9 377 
2229 1-naphthalene 0 2 1 3.5 0.46 93.9 206 
2266 9-anthracene 0 1 1 0.1 0.59 131 222 
2261 1-naphthalene 0 1 1 3.4 0.69 134 194 
2228 4-quinoline 0 0 1 4.3 2.0 >147.6 73.8 
2269 1-naphthalene 0 1 2 5.1 2.56 54 21 
2268 1-naphthalene 0 2 2 3.6 3.05 87.5 28.7 
2263 N/A N/A N/A N/A 10.1 9.2 37.1 4.0 
2292 2-naphthalene 2 0 1 4.8 ND ND ND 
2294 2-naphthalene 3 0 1 2.8 ND ND ND 
a) Data kindly provided by Dr. Shuo Wang, Georgia State University. 
b) Data kindly provided by Dr. Reto Brun, Swiss TPH Basel, Switzerland. 
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In conclusion, we have discovered a new hit for treatment of African Sleeping Sickness, 
DB 2262, with sub-micromolar activity (IC50 = 0.26 µmol) and good selectivity (SI = 377).  The-
se monoamidine compounds represent a new class of potential therapeutics for this disease.  We 
have observed that there is little correlation between in vitro IC50 values and DNA ∆Tm data.  
This suggests that either a different DNA model is needed to evaluate these compounds or the 
mechanism of action is not related to DNA binding. 
3.2  Potential DAPI boron derivatives 
There is some literature on the chemistry of dioxa- and diazaboroles112,113,114,115,116,117,118, 
but the properties of these compounds have not been thoroughly studied.  To the best of our 
knowledge, the only report of microwave assisted synthesis of diazaboroles is that of Slabber et 
al.91 which involved heating the reactants to 150 oC in a microwave reactor without solvent.  
Starting material had to be finely milled using the Slabber method before microwave irradiation 
in order to be highly effective.  The method employed for this dissertation uses microwave irra-
diation with toluene or EtOH / toluene (1:1) as solvent and does not require milling the starting 
materials (equation 16).  It was found that the use of solvent made purification more simple as 
the unreacted started material would stay in solution.  Conventional synthetic methods for these 
diazaboroles take between several hours to overnight83,119,, but the reaction time is shortened to 
just 10 minutes using microwave irradiation.  This synthetic route to these potential boron DAPI 
derivatives is more facile than the synthesis of the biscyanoindole-phenyl core needed for DAPI 
synthesis34 (see Equation 22) and offers a unique advantage to synthesis of the diazaborole DAPI 
analogues.  This reaction involves no metal catalysts, is clean, and requires minimal purification 
efforts.   
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Synthesis of diazaboroles proceeded by microwave irradiation at 200 W of 1:1 equiva-
lents of a boronic acid and phenylenediamine at temperatures of either 115 – 135 oC in anhy-
drous toluene (PhMe).  Temperatures over 135 oC sometimes resulted in product decomposition.  
Diazaborole formation could be quickly identified by 1H-NMR with a singlet or pair of N-H sin-
glets between 9.5 – 9.9 ppm.  (For the remainder of this section, all NMR data was obtained us-
ing DMSO-d6 as solvent because some compounds have low solubility in CDCl3.)  In some cas-
es, the pair of singlets reduced to one singlet between 9.3 – 9.6 ppm (for example XXIII and 
XXIV). 
Equation 22  Condensation of phenylene diamine with boronic acid in toluene heating by microwave irradiation 
 
3.2.1 Properties of Diazaborole 
Substituting diazaboroles (an indole isostere120,121,122) for indoles offer several chemical 
property enhancements that are appealing.  Hydrophilicity is able to be modified by introducing 
boron into a compound (Figure 21).  For example, by using Hartree-Frock under 3-21G condi-
tions in Spartan, the clog P of 2-phenyl-1H-indole, the core moiety of DAPI, is 4.23.  The cLog 
P of 2-phenyl-2,3-dihydro-1H-benzo[d][1,3,2]diazaborole, the boron isostere of 2-phenyl-1H-
indole, is 2.71. 
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To estimate if diazaboroles are aromatic, models of the compounds were examined in 
Spartan using Hartree-Fock under 3-21G conditions.  The corresponding N1-C2 and C2-X3 bond 
lengths in other cyclic compounds – indole, benzimidazole, indoline, and benzimidazoline – 
were compared (Table 5).  Indole, the isostere of diazaborole, has a N1-C2 bond length of 1.39 
Å, C2-C3 bond length of 1.36 Å, N1-H1 bond length of 0.995 Å, C3-H3 bond length of 1.07 Å, 
and a dihedral angle for the N1-C2-C1’-C2’ atoms of 35.2o.  For the diazaborole, the correspond-
ing N1-B2 and B2-N3 bond lengths are 1.44 A, N1-H1 and N3-H3 bond lengths are 0.997 Å, 
and the dihedral angle for the N1-B2-C1’-C2’ atoms is 25.81o.  The diazaborole average bond 
angles about the boron and nitrogen centers (127.71o, 127.86o, 109.45o) correspond more closely 
to the corresponding atom centers in the aromatic molecules indole (121.38o, 129.73o, 109.36o) 
and benzimidazole (123.90o, 124.50o, 107.96o) than the corresponding atom centers in the non-
aromatic portions of indoline (112.77o, 111.45o, 112.48o) and benzimidazoline (112.71o, 112.71o, 
112.16o).   
Using the previous calculation method in Spartan, models of diazaborole compounds 
XXIII – XXX were produced.  Compounds XXIII – XXX had an average calculated bond 
lengths of 1.45 Å and 1.44 Å for the N1-B2 and B2-N3 bonds respectively (Table 6), and 0.997 
                 
      clog P = 4.23        clog P = 2.71      
 A       B 
Figure 21  The core of DAPI, 2-phenyl-1H-indole (A), 2-phenyl-2,3-dihydro-1H-
benzo[d][1,3,2]diazaborole (B), and 2-phenylbenzo[d][1,3,2]dioxaborole (C).  
Table 5  Calculated bond angles, dihedral angle, and bond lengths of indole, benzimidazole, diazaborole, imidazoline, 
and benzimidazoline 
 
 
N1-Y2-X3 N1-Y2-C1’ X3-Y2-C1’ C9-N1-Y2 C4-X3-Y2
Dihedral 
Angle
N1-Y2 X3-Y2 Y2-C1’ C9-N1 C4-X3
Indole 108.88 121.38 129.73 109.36 107.58 36.25 1.39 1.36 1.47 1.38 1.44
Benzimidazole 111.60 123.90 124.50 107.96 106.69 0.00 1.38 1.30 1.47 1.38 1.40
Diazaborole 104.34 127.82 127.84 109.51 109.51 25.81 1.44 1.44 1.56 1.40 1.40
Indolizine 102.85 112.77 111.45 112.48 103.59 33.66 1.47 1.58 1.52 1.38 1.52
Benzimidazoline 100.18 112.71 112.71 112.16 112.16 56.25 1.47 1.47 1.52 1.39 1.39
Bond Length (A)Bond Angle (
o
)
Heterocycle
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Å for the N1-H1 and N3-H3 bond lengths (Table 7).  Further exploration of these models 
88 
showed an average dihedral angle of 27.53o for the N1-B2-C1’-C2’ atoms.  The N1-B2 / N3-B2 
     
     
            
           
  
XXIII 
XXV 
XXX 
XXIV 
XXVI 
XXIX 
XXXI 
XXVII XXVIII 
Figure 22  Benzo[d][1,3,2]diazaboroles XXIII - XXXI 
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bond lengths are in line with literature values obtained from computational and crystallography 
data86,87,91,119,123,124, and the average dihedral angle agrees with the dihedral angle data for 
benzo[d]1,3,2-diazaborole shown in Table 5. 
In the aromatic molecule borazine, the B-N bond distances range from 1.42 – 1.44 Å88.  
The calculation results for diazaboroles, 1.44 – 1.45 Å, corresponds rather well to the bond 
length of the aromatic B-N system borazine and is between the B-N single bond length of 1.58 Å  
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and the B=N double bond length of 1.40 Å92.  One of the important clues that diazaborole exhib-
its aromatic character is that the benzodiazaborole ring system is planar according to Spartan cal-
culations and literature crystal structures119.  Despite having an empty p orbital, the diazaborole 
and the diazaborole-phenyl ring system may maintain conjugation and aromaticity by B-N back 
bonding and orbital overlap with the empty boron pz orbital. 
Table 6 Calculated bond angles, dihedral angle, and bond lengths of compounds XXIII – XXX 
 
 
N1-B2-N3 N1-B2-C1’ N3-B2-C1’ C9-N1-B2 C4-N3-B2
Dihedral 
Angle
N1-B2 N3-B2 B2-C1’ C9-N1 C4-N3
XXIII 104.39 127.77 127.84 109.44 109.47 26.52 1.44 1.44 1.56 1.40 1.40
XXIV 104.60 127.69 127.71 109.33 109.36 28.44 1.44 1.44 1.56 1.40 1.40
XXV 104.23 127.73 128.04 109.50 109.60 26.16 1.45 1.44 1.56 1.39 1.40
XXVI 104.44 127.89 127.66 109.39 109.48 28.16 1.44 1.45 1.56 1.40 1.39
XXVII 104.52 127.51 127.97 109.47 109.37 28.12 1.45 1.44 1.56 1.39 1.40
XXVIII 104.34 127.71 127.95 109.54 109.45 27.63 1.45 1.44 1.56 1.39 1.40
XXIX 104.41 127.56 128.03 109.53 109.44 27.66 1.45 1.44 1.56 1.39 1.40
XXX 104.49 127.83 127.68 109.41 109.43 27.58 1.44 1.44 1.56 1.40 1.40
Average 104.43 127.71 127.86 109.45 109.45 27.53 1.45 1.44 1.56 1.40 1.40
Diazaborole
Bond Angle (
o
) Bond Length (A)
Table 7 Calculated bond lengths of N-H and 
C-H bonds (where applicable) contrasting the 
difference in bond lengths for HBD’s and non 
HBD’s 
 
 
Heterocycle
N1-H 
bond 
length 
(A)
C3-H 
bond 
length 
(A)
Indole 0.995 1.06
Benzimidazole 0.993 -----
Diazaborole 0.997 -----
Indolizine 0.995 1.08
Benzimidazoline 0.993 -----
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3.2.2 Diazaborole chemistry 
92 
It is hypothesized that the B-N back bonding which partially fills the empty p orbital in 
93 
boron may prevent nucleophilic or base attack on the boron.  Additionally, the B-N back bonding 
94 
should form a partial negative formal charge on the boron providing electron repulsion to 
95 
nucleophilic / base attack.  However, the labile B-N bond in diazaboroles suggests differently.  It 
96 
was noted in work done by Islas et al.88 that borazine is more susceptible to addition reactions 
97 
despite its aromaticity and that reformation of aromaticity is not the driving force in its chemis-
try.  No similar work has been found for diazaborole.  Nonetheless, it was believed that amidines 
could be synthesized by the Pinner method due the work of Letsinger and Hamilton125 which 
suggested stability in HCl; however, synthesis proved unsuccessful (see below).  Diazaboroles 
XXIII – XXV were found to cleave in alcohols.  Moreover, this series of compounds were ex-
tremely sensitive to acid and base conditions preventing amidine synthesis by the Pinner reac-
tion; by the Liebeskind-Srogl reaction which involves carbon-carbon coupling of a protected 
thioamidine to a boronic acid126,127; nucleophilic addition of lithium bis(trimethylsilyl)amide 
(LiHMDS) to the nitrile to form an amidine128, and the acid-chloride method which involves am-
ide synthesis from a carboxylic acid with thionyl chloride followed by exposure to ammonium 
 
Scheme 9  Examples of attempted methods of synthesizing amidines for the diazaborole DAPI derivative A) LiHMDS 
A 
B 
Scheme 8  Examples of attempted methods of synthesizing amidines for diazaborole DAPI derivative A) LiHMDS method 
on XXVI B) from carboxylic acid XXX 
XXVI 
98 
carbonate, converting the amide to the imidoyl chloride with thionyl chloride, and then final 
conversion to the amidine with ammonium carbonate129 (see Scheme 8).  It was then thought that 
Boc-protection of the amines of on XXVI may prevent cleavage by blocking attack on the empty 
p-orbital of boron; nevertheless, when subjected to the LiHMDS method to make the amidine, 
cleavage occurred.  
To obtain the dihydrochloride salt of compounds XXIII – XXVI using the method 
Letsinger and Hamilton125 employed for benzo[d]1,3,2-diazaborole, XXIII – XXVI were stirred 
in anhydrous toluene heated to 80 oC while passing anhydrous HCl through the mixture, and 
stirred for 8 hours.  All of the diazaboroles subjected to the Letsinger and Hamilton method were 
cleaved except the bis-cyano derivative XXVI which underwent neither cleavage nor salt for-
mation.  The mono-cyano derivatives, XXIV and XXV, formed approximately 50% mixtures of 
cleavage product and recovered starting material.  This apparent stability is probably because 
nitriles are strong electron withdrawing groups, removing electron density from the aromatic ring 
system, and making it less likely that the nitrogen lone pair will become protonated to form an 
unstable ammonium-boron intermediate.  It is worth mentioning that the only literature claiming 
formation of the dihydrochloride salt is that of Letsinger and Hamilton and no other such reports 
were found.  Cleavage was also observed when the diazaborole XXIV was stirred in PhMe HCl 
at room temperature and at 0 oC. 
In another attempt to make the diazaborole DAPI derivative, it was decided to make car-
boxylic acid and amide derivatives.  The aim was to make amides from the carboxylic acid using 
acid chloride and an ammonium salt in DCM, imidoyl chlorides from the amide using thionyl 
chloride, and finally amidines from the imidoyl chlorides using an ammonium salt.  Condensa-
tion of (4-carbamoylphenyl)boronic acid substrate with 4-bromo-, 4-cyano, 4-amidino-, and o-
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phenylenediamine proved unsuccessful, but the 4-carboxyphenylboronic acid substrates readily 
formed diazaboroles.   
The acid chloride strategy for amidine synthesis was employed with XXIX and XXX, but 
this method resulted in B-N bond cleavage.  To see if adding a carboxylic acid had any positive 
effect on dihydrochloride salt formation, the Letsinger and Hamilton method125 was attempted 
with compounds XXVII – XXIX, but again only cleavage occurred.  It is noteworthy that only 2 
compounds were partially cleaved under these conditions, again those with mono nitrile substitu-
tion, XXVIII and XXIX.  It is noteworthy that formation of diazaboroles via condensation with 
either 3,4-diaminobenzoic acid hydrochloride salt or 4-carboxyphenylboronic acid hydrochloride 
salt with the appropriate substrate gave drastically reduced yields (less than 5 %).  In a final at-
tempt to make amidino-diazaborole, 3,4-diaminobenzamidine hydrochloride was allowed to re-
act with various boronic acids in PhMe; no reaction was observed except with 4-
carboxyphenylboronic acid which showed ~50 % conversion based upon 1H-NMR spectra.  Alt-
hough EtOH alone caused B-N bond cleavage of coumpounds XXIII – XXV, it was known 
through work by Kelly et al. that cleavage by EtOH is not a property of all diazaboroles.  Kelly 
et al. synthesized 2-(4’-methoxyphenyl)-5-methyl-2,3-dihydro-1H-1,3,2-benzodiazborole using 
ethanol as a solvent130.  Knowing that 3,4-diaminobenzamidine hydrochloride is soluble in etha-
nol and 4-carboxyphenylboronic acid is sparingly soluble in warm EtOH, it was hypothesized 
that using EtOH as solvent would lead to higher conversion to XXX.  However, use of EtOH as 
solvent resulted in no reaction.  Consequently, PhMe was added in various ratios to EtOH (3:1, 
2:1, 1:1) and still no reaction was noted.  It was later found that adding excess of boronic acid 
resulted in higher conversion. Optimization of this reaction resulted in the synthesis of XXX 
from 1 eq. of 3,4-diaminobenzamidine with 2 eq. of 4-carboxyphenylboronic acid in EtOH / 
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PhMe (1:1) with 60 % yield.  This optimized method did not work for other boronic acid sub-
strates.  
 Unlike the other diazaboroles XXIII – XXIX, XXX is resistant to cleavage in EtOH 
most likely because of the strong electron withdrawing ability of the amidine salt, similar to the 
resistance of XXVI to cleavage in hydrochloric acid in toluene.  Moreover, unlike previous at-
tempts to synthesize diazaboroles with the hydrochloride salts of carboxylic acids or amides, the 
amidine hydrochloride salt of phenylenediamine was found to have limited reactivity, only react-
ing with 4-carboxyphenylboronic acid to form XXX.  
The properties of this series of diazaboroles can be explored with 1H and 11B NMR data.  
1H NMR data suggests that the amines are very acidic.  A D2O exchange experiment readily ver-
ifies that the peaks between 9.3 – 9.9 ppm are the diazaborole-amines.  Amines usually exhibit 
proton shifts of 0.5 – 4 ppm for primary and 3 - 6 ppm for secondary ones131.  3,4-
Diaminobenzonitrile amines have chemical shifts of 5.43 and 4.85 in DMSO-d6, and the amine 
of indole has a chemical shift of 8.13132.  The shift down to 9.3 – 9.9 ppm is indicative of elec-
tron sharing of the nitrogen lone pairs in the ring anisotropy and aromaticity.  Interestingly, am-
ides have chemical shifts of 6.0 – 9.5 ppm131.  The proton chemical shifts of diazaboroles to 9.3 – 
9.9 ppm, similar to the extreme end of amide chemical shifts, is indicative of an electron with-
drawing effect.  In the case of diazaboroles, the large downfield chemical shift for the N-H pro-
tons is likely due to a contribution of the electronic withdrawing effect, presumably coming from 
the empty pz orbital, and the ring current effect as a consequence of the aromaticity of the 
heterocycle. 
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The downfield shift of the NH signals for diazaboroles can be attributed to the electron 
withdrawing effect presumably resulting from the empty boron pz orbital and to the ring current 
effect.   It was noticed that compounds XXVII – XXX exhibited two single peaks for the amines 
whereas compounds XXIII – XXVI had one.  It is reasonable to assume that the 2 peaks were a 
result of different environments because of the substitution at the 6 position of the 
benzodiazaborole ring.  For example, compound XXVI has one peak for the amines with a cyano 
groups at both the 6 position of the benzodiazaborole ring and the 4’ position of the phenyl ring, 
but compound XXVIII has two peaks for the amines with a cyano group at 6 benzodiazaborole 
position and a carboxylic acid at the 4’ position of the phenyl ring.  The 6 position on the 
benzodiazaborole ring is the same in both XXVI and XXVIII, but the amines have two different 
characteristics for their 1H NMR spectra: 1 peak for XXVI and 2 peaks for XXVIII.  Conse-
quently, we conclude that one NH peak for XXVI is an example chemically unequivalent pro-
tons being magnetically equivalent. 
11B NMR data was also obtained for compounds XXIII – XXXI.  As stated in the intro-
duction, the nitrogen lone pairs can back bond to the boron empty p-orbital.  This phenomenon 
makes proton abstraction from the nitrogen more likely as the nitrogen can share the increased 
electron density with the ring system and the empty boron p-orbital.  11B NMR of XXIII – XXX 
shows chemical shifts ranging from 18.30 – 18.91 (with boric acid as an internal standard in 
DMSO-d6), and the width at half height for the peaks range from 341.5 – 396.0 Hz.  Boron is 
known to be more prone to the influence of inductive effects in 11B NMR than NMR of other nu-
clei and substantially less affected by substituent effects, i.e. 1H or 13C, which explains the small 
difference in 11B chemical shifts among the  diazaboroles XXIII – XXXII (Table 8)133,134.  4-
Carboxyphenylboronic acid has a chemical shift of 18.4 ppm.  As 
 
Figure 23  XXXII 
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far as the author can tell, there is no 11B NMR data of diazaboroles in DMSO-d6; most data of 
these types of compounds are in CDCl3.  The author is forced to use DMSO-d6 as the solvent 
since some of the compounds are insoluble in CDCl3.  A 11B NMR spectrum of XXXII in CDCl3 
was obtained with a chemical shift of 28.63 ppm, about a 10 ppm difference from the chemical 
shift in DMSO-d6 which is 18.91 ppm (boric acid was used as the internal standard for both sol-
vents).  
Table 8  11B NMR data for compounds XXIII - XXXII 
 
# δ ppm 
XXIII 18.41
XXIV 18.59
XXVI 18.44
XXVII 18.58
XXVIII 18.45
XXIX 18.41
XXX 18.48
XXXI 18.30
XXXII 18.91
Compound
N
H
B
H
N
CO2H
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The pKa for diazaboroles has not been determined experimentally, most likely due to its 
instability in acid and basic media.  However, benzo[d]1,3,2-diazaborole pKa has been calculat-
ed using ACD Labs Software to be 3.9984.  The pKa of the corresponding indole analogue (2-
phenyl-1H-indole) is 16.8 and for the benzimidazole analogue (2-phenyl-1H-benzo[d]imidazole) 
is 11.484.  With a significantly lower pKa, the amines of diazaboroles should be better HBD, 
making investigations on stabilizing diazaboroles for therapeutic purposes worthwhile. 
 A number of diazaborole compounds have been synthesized in an attempt to make a bo-
ron DAPI derivative.  Most of the compounds were quite sensitive to ethanol as well as both acid 
and base conditions making synthesis of amidines difficult.  However, we were able to synthe-
size the monoamidine XXX.  Further work needs to be done on diazaboroles to elucidate their 
chemistry and properties to determine if the synthesis of a diazaborole DAPI derivative is possi-
ble.     
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4     CONCLUSIONS 
3.3 DB818 combilexins 
Loss of one amidine on DB818 greatly reduces the binding affinity on the DB818 frag-
ment-intercalator hybrid compounds.  The loss of one amidine was not compensated for by the 
intercalating unit or triazole moieties.  Results also show that lengthening the linkers does not 
lead to higher DNA binding affinities.  Data from T. b. r. IC50 values and cytotoxicity studies 
show that DB2262 and 2266 are good hits for this parasite (IC50 = 0.26 and 0.59 µmol respec-
tively) with good selectivity (SI = 377 and 222, respectively) and deserve further exploration.   
3.4 DAPI boron derivatives 
Synthesis via microwave irradiation offers a quick way to synthesize benzodiazaboroles 
that would otherwise take hours using conventional methods.  The advantages of microwave ir-
radiation were exploited to make novel diazaboroles.  Compound XXX is novel in that it is the 
first monoamidine-diazaborole compound reported.  Further work should be done to explore the 
chemistry of diazaboroles in order to see if there are any useful biological properties of these 
novel compounds, particularly XXX.    
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